Steroid compound, and use thereof and preparation method therefor

Abstract

To provide a steroid compound that is expected to effectively treat mental and neurological diseases and offer superior active efficacy, pharmacokinetic (PK) performance, oral bioavailability, stability, safety, clearance rate, and / or metabolic performance and the like, uses thereof and preparation methods therefor.SOLUTION: The present invention provides a pharmaceutical composition comprising a compound represented by formula (II) with a specific substituent, or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to the field of medicine, in particular to steroid compounds, their uses and their preparation methods. [Background technology]

[0002] Neuropsychiatric disorders include anxiety, depression, schizophrenia, etc., which rank first among all diseases in China, accounting for about 20% of all diseases in China (Wang Juncheng et al., China Health Service Management, 2009(5): 348-350). With the continuous social modernization, accelerating work rhythm, and increasing life burden, the number of patients with various neuropsychiatric disorders has increased dramatically, and the progression of symptoms has accelerated significantly, making the development, research and production of new drugs to treat these diseases more urgent. Meanwhile, clinical data suggests that many patients are simultaneously affected by various neuropsychiatric disorders. The high prevalence of co-morbidity of neuropsychiatric disorders makes clinical treatment face greater challenges.

[0003] In animals, GABA (gamma-aminobutyric acid) (γ-aminobutyric acid) is found exclusively in nervous tissues, and immunological studies have shown that the highest concentrations of GABA are found in the substantia nigra. GABA is an important inhibitory neurotransmitter and has been studied in depth. GABA is involved in various metabolic activities and has high physiological activity. The GABA system is the main inhibitory signaling pathway in the brain and central nervous system and is of great significance for the function of the central nervous system. GABA(A) receptors (GABAAR) are ion receptors and ligand-gated ion channels. Its endogenous ligand γ-aminobutyric acid (GABA), the main inhibitory neurotransmitter, is found in the central nervous system. After activation of GABA(A) receptors, extracellular Cl is released into the brain and the central nervous system. - is selectively allowed to pass through the pore of the GABA receptor. -GABAergic pathways flow out of neuronal cells when the inner potential is lower than the resting potential and flow into neuronal cells when the inner potential is higher than the resting potential (i.e. -75mv). This successfully reduces the likelihood of action potentials and inhibits neurotransmission. Anxiety and depression have a very high co-morbidity and are thought to be overlapping and co-occurring phenomena. Anxiety and depression are also important psychiatric symptoms of schizophrenia. Research results have confirmed the important role of the GABAergic system and GABA(A) receptors in the etiology and pathology of these three diseases, and indicated that the pathophysiological process related to the GABAergic system may be one of the determinants of all three diseases. The GABAergic system and GABA(A) receptors have been shown to be involved in the pathological processes of anxiety, depression and schizophrenia at the molecular, preclinical and clinical levels, and GABA(A) receptors have long been used as important drug targets in the treatment of these diseases.

[0004] In addition to binding to GABA itself and forming receptor complexes (GRCs) to alter brain excitability, clinical trials have confirmed that GABA(A) receptors can bind to other small molecule compounds, such as barbiturates (trade name: sodium secobarbital) and benzodiazepines (trade name: diazepam). Each of these drugs binds to a specific allosteric site on the GABA(A) receptor to exert its therapeutic effects. Furthermore, studies have shown that there is a unique binding site on the GABA(A) receptor for steroid compounds (Lan, NC et al., Neurochem. Res. 16: 347-356 (1991)).

[0005] Neuroactive steroids can occur endogenously. The most potent endogenous neuroactive steroids are 3α-hydroxy-5-reduced pregnan-20-one and 3α-21-dihydroxy-5-reduced pregnan-20-one, which are metabolites of the hormonal steroids progesterone and deoxycorticosterone, respectively. The ability of these steroid metabolites to change brain excitability was recognized in 1986 (Majewska, MD et al., Science 232: 1004-1007 (1986); Harrison, NL et al., J. Pharmacol. Exp. Ther.241:346-353 (1987)). The ovarian hormone progesterone and its metabolites have been demonstrated to have profound effects on brain excitability (Backstrom, T. et al, Acta Obstet. Gynecol. Scand. Suppl. 130: 19-24 (1985); Pfaff, DW and McEwen, BS, Science 219:808-814 (1983); Gyermek et al, J Med Chem. 11 : 117 (1968); Lambert, J. et al, Trends Pharmacol. Sci. 8:224-227 (1987)). Concentrations of progesterone and its metabolites vary with the phase of the menstrual cycle. It is well documented that concentrations of progesterone and its metabolites decrease before the onset of menstruation. It is also well documented that certain physical symptoms recur monthly before the onset of menstruation. These symptoms have come to be associated with premenstrual syndrome (PMS) and include stress (tension), anxiety, and migraines (Dalton, K., Premenstrual Syndrome and Progesterone Therapy, 2nd edition, Chicago Yearbook, Chicago (1984)). Subjects with PMS have symptoms that recur monthly and are present before menstruation and not present after menstruation.

[0006] Other studies have found that a decrease in progesterone is associated with increased seizure frequency in female patients with epilepsy (Laidlaw, J., Lancet, 1235-1237 (1956)). A more direct correlation has been observed with a decrease in progesterone metabolites (Rosciszewska et al, J. Neurol. Neurosurg. Psych. 49:47-51 (1986)). Also, for subjects with primary generalized petit mal epilepsy, the temporal incidence of seizures correlates with the incidence of premenstrual syndrome symptoms (Backstrom, T. et al, J. Psychosom. Obstet. Gynaecol. 2:8-20 (1983)). The steroid deoxycorticosterone has been found to be effective in treating subjects with epileptic seizures that correlate with the menstrual cycle (Aird, RB. and Gordan, G, J. Amer. Med. Soc. 145:715-719 (1951)).

[0007] Also associated with low progesterone levels is postpartum depression (PPD). Immediately after childbirth, progesterone levels fall dramatically, leading to the development of PPD. PPD symptoms range from mild depression to psychosis requiring hospitalization. PPD is also associated with severe anxiety and irritability. PPD is not amenable to treatment with classical antidepressants, and women experiencing PPD show an increased incidence of PMS (Dalton, K., Premenstrual Syndrome and Progesterone Therapy, 2nd edition, Chicago Yearbook, Chicago (1984)). Taken together, these observations imply that progesterone and deoxycorticosterone, and more specifically their metabolites, play a key role in the homeostatic regulation of brain excitability, which is evident in the increased seizure activity or symptoms associated with menstrual-associated epilepsy, PMS, and PPD.

[0008] Many studies are based on GABA(A) receptors to obtain drugs that can effectively treat related diseases. CN103958540A, CN10533928A, etc. disclose a series of neurosteroid compounds for the treatment of neuropsychiatric diseases. GABA(A) is a subtype of gamma-aminobutyric acid receptor (GABAR), and GABAR has three subtypes: GABA(A), GABA(B) and GABA(C). GABA(A) is a chloride ion channel.

[0009] GABA(A) is composed of five subunits (polypeptide chains) that form a heteropentameric structure. Two pairs of the five subunits are identical, so a specific GABA(A) receptor has three types of subunits, commonly known as α, β, and γ. Each subunit has several different subtypes: α has α1, α2, α3, α4, α5, and α6; β has β1, β2, and β3; and γ has γ1, γ2, γ3, and γ4. In addition, δ, ε, ρ 1~3 There are subunits such as , θ, π, and can form pentamers with α and β.

[0010] According to statistics, there are a total of 23 GABA(A) receptors with different subunit combinations. The specific isoforms of the receptors are related to the distribution area of ​​neurons in the brain. For example, GABA(A) receptors containing γ subunits are mainly located inside synapses, while GABA(A) receptors containing δ subunits are mainly distributed outside synapses (extrasynaptic). (Activation of GABA(A) Receptors: Views from Outside the Synaptic Cleft, Neuron, Vol 56, 2007, 763-770); one study (Endogenous neurosteroids regulate GABA(A) receptors through two discrete transmembrane sites:Nature.Vol 444.23 November. 2006.486-489) showed that endogenous steroids such as tetrahydrodeoxycorticosterone (THDOC) at high concentrations (micromolar levels) inhibit the activation of GABA receptors α1β2γ2 (hereafter referred to as GABA A1 We showed that it directly activates the GABA receptor α1β2γ2 at low concentrations (submicromolar levels), while enhancing the GABA receptor α1β2γ2.

[0011] [ka]

[0012] However, extrasynaptic receptor subtypes (such as α4β3δ, hereafter referred to as GABA A4 There have been no reports of steroid compounds that can directly activate the steroid hormone agonist (hereinafter referred to as agonist). Summary of the Invention

[0013] One of the objectives of the present invention is to provide a steroid compound that can treat neurological diseases more effectively. The compound of the present invention is expected to provide good efficacy, pharmacokinetic (PK) properties, oral bioavailability, formulation feasibility, stability, safety, clearance, and / or metabolism, and to reduce side effects such as sensory anesthesia and sedation.

[0014] With the above objects in view, the present invention provides a compound of formula (I), or a pharma- ceutically acceptable salt thereof:

[0015] [ka]

[0016] During the ceremony, R1 is hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, or substituted or unsubstituted C3-6 carbocyclyl.

[0017] R2 is hydrogen, halogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 carbocyclyl.

[0018] R3 is hydrogen, unsubstituted C1-6 alkyl, or -CH2OR a where R a is hydrogen, substituted or unsubstituted C1-6 alkyl, substituted or unsubstituted C1-6 alkoxy, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted C3-6 carbocyclyl.

[0019] L is -C(Rb)(Rb)-, each Rb is independently hydrogen or C1-C6 alkyl, and n is an integer from 0 to 3.

[0020] R4 is halogen, or substituted or unsubstituted heteroaryl or heterocyclyl.

[0021] Further preferred compounds are R1 is hydrogen, substituted or unsubstituted C1-6 alkyl; R2 is hydrogen, substituted or unsubstituted C1-6 alkyl; R3 is hydrogen, unsubstituted C1-6 alkyl; Rb is hydrogen and n is an integer from 1 to 2; R4 is optionally cyano, nitro, hydroxy, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, -C(O)Rd, -C(O)N(Re)(Rf), -C(O)O(Rd), -N(Re)(Rf), -OC(O)N(Re)(Rf), -OC(O)O(Rd), -OC(O)Rd, -S(O) 0~2 Rd, -S(O) 0~2 ORd, or -S(O) 0~2 heteroaryl substituted with N(Re)(Rf); Each Rd is independently hydrogen or C1-C6 alkyl; Each of Re and Rf is independently hydrogen, C1-C6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl.

[0022] Further preferred compounds are R1 is hydrogen or methyl; R2 is hydrogen; R3 is hydrogen; L is -CH-; R4 is a monocyclic or bicyclic heteroaryl, or a monocyclic or bicyclic heterocyclyl, each heteroatom being oxygen, nitrogen or sulfur, and the bicyclic ring may be spiro or fused.

[0023] Further preferred compounds are R4 is a 5- or 6-membered heteroaryl containing 2-4 nitrogen atoms, optionally substituted with cyano, nitro, hydroxy, halo, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl.

[0024] Or a compound as shown in formula II:

[0025] [ka]

[0026] During the ceremony, R1 is hydrogen or a halogen substituted or unsubstituted C1-3 alkyl group; R2 is hydrogen, halogen, a halogen-substituted or unsubstituted C1-6 alkyl group, or a halogen-substituted or unsubstituted C1-6 alkoxy group; X is CH, N, O, or S; R5 is selected from the group consisting of:

[0027] [ka]

[0028] During the ceremony, R6 is H, halogen, CN, CF3, NO2, halogen-substituted or unsubstituted C1-6 alkyl, or halogen-substituted or unsubstituted C1-6 alkoxy.

[0029] Alternatively, preferred compounds are selected from the following:

[0030] [ka] JPEG2024170486000006.jpg35169

[0031] [ka]

[0032] [ka]

[0033] The present invention also provides pharmaceutical compositions comprising the above compound, or any of its pharma- ceutically acceptable salts, or a pharma- ceutically acceptable excipient.

[0034] The present invention also provides compounds as described herein that can act as GABA modulators, such as by positively or negatively affecting GABA(A) receptors. As modulators of central nervous system (CNS) excitability, such compounds are expected to have CNS activity by virtue of their ability to modulate GABA(A) receptors.

[0035] The present invention further provides the use of the compound or pharmaceutical composition described herein in the prevention or treatment of neurological disorders.The neurological disorders are preferably selected from sleep disorders, mood disorders, schizophrenia spectrum disorders, spastic disorders, memory disorders and / or cognitive disorders, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular disorders, substance abuse disorders and / or withdrawal syndromes, or tinnitus; the mood disorders are depression, and the depression is major mood disorders, severe depressive disorders, persistent depressive disorders, premenstrual syndrome, substance- or drug-induced disorders, physical illness disorders, other specified depressive disorders, and unspecified depressive disorders, and is preferably mild depression, moderate depression, severe depression, or postpartum depression.The compound or pharmaceutical composition can also be administered orally, subcutaneously, intravenously, or intramuscularly.

[0036] [Definition] [Chemical definition] The compounds described herein may contain one or more asymmetric centers and therefore may exist in various isomeric forms, such as enantiomers and / or diastereomers. For example, the compounds described herein may be in the form of individual enantiomers, diastereomers or geometric isomers, or may be in the form of a mixture of stereoisomers. Such mixtures include racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric synthesis.

[0037] The following terms are intended to have the following meanings provided therewith and are useful for understanding the description and intended scope of the present invention. When describing the present invention, it can include compounds, pharmaceutical compositions containing the compounds, and compounds and compositions of test methods. For definitions of terms included in the present invention, reference can be made to the following description, and any of the moieties defined below may be substituted with a number of substituents. Corresponding definitions are within their scope listed below, including such substituted moieties. Unless otherwise specified, the term "substituted" is as defined below.

[0038] "Alkyl" refers to a linear or branched saturated hydrocarbon group having 1 to 20 carbon atoms ("C1-20 alkyl"). In some embodiments, an alkyl group has 1 to 12 carbon atoms ("C1-12 alkyl"). In some embodiments, an alkyl group has 1 to 10 carbon atoms ("C1-10 alkyl"). In some embodiments, an alkyl group has 1 to 9 carbon atoms ("C1-9 alkyl"). In some embodiments, an alkyl group has 1 to 8 carbon atoms ("C1-8 alkyl"). In some embodiments, an alkyl group has 1 to 7 carbon atoms ("C1-7 alkyl"). In some embodiments, an alkyl group has 1 to 6 carbon atoms ("C1-6 alkyl", also referred to herein as "lower alkyl"). In some embodiments, an alkyl group has 1 to 5 carbon atoms ("C1-5 alkyl"). In some embodiments, an alkyl group has 1 to 4 carbon atoms ("C1-4 alkyl"). In some embodiments, an alkyl group has 1 to 3 carbon atoms ("C1-3 alkyl"). In some embodiments, an alkyl group has 1 to 2 carbon atoms ("C1-2 alkyl"). In some embodiments, an alkyl group has 1 carbon atom ("C1 alkyl"). In some embodiments, an alkyl group has 2 to 6 carbon atoms ("C2-6 alkyl"). Examples of C1-6 alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), isobutyl (C4), n-pentyl (C5), 3-pentanyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), and n-hexyl (C6). Further examples of alkyl groups include n-heptyl (C7), n-octyl (C8), and the like. Unless otherwise specified, each example alkyl group is independently optionally substituted, i.e., unsubstituted (an "unsubstituted alkyl") or substituted (a "substituted alkyl") with one or more substituents, e.g., 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.In certain embodiments, the alkyl group is an unsubstituted C1-10 alkyl (eg, -CH3). In certain embodiments, the alkyl group is a substituted C1-10 alkyl.

[0039] "Alkenyl" refers to a straight-chain or branched hydrocarbon group having 2 to 20 carbon atoms, one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 carbon-carbon double bonds), and optionally one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 carbon-carbon triple bonds) ("C2-20 alkenyl"). In certain embodiments, the alkenyl does not contain any triple bonds. In some embodiments, an alkenyl group has 2 to 10 carbon atoms ("C2-10 alkenyl"). In some embodiments, an alkenyl group has 2 to 9 carbon atoms ("C2-9 alkenyl"). In some embodiments, an alkenyl group has 2 to 8 carbon atoms ("C2-8 alkenyl"). In some embodiments, an alkenyl group has 2 to 7 carbon atoms ("C2-7 alkenyl"). In some embodiments, an alkenyl group has 2-6 carbon atoms ("C2-6 alkenyl"). In some embodiments, an alkenyl group has 2-5 carbon atoms ("C2-5 alkenyl"). In some embodiments, an alkenyl group has 2-4 carbon atoms ("C2-4 alkenyl"). In some embodiments, an alkenyl group has 2-3 carbon atoms ("C2-3 alkenyl"). In some embodiments, an alkenyl group has 2 carbon atoms ("C2 alkenyl"). One or more of the carbon-carbon double bonds may be internal (such as 2-butenyl) or terminal (such as 1-butenyl). Examples of C2-4 alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2-6 alkenyl groups include the C2-4 alkenyl groups mentioned above, as well as pentenyl (C5), pentadienyl (C5), hexenyl (C6), etc. Further examples of alkenyl include heptenyl (C7), octenyl (C8), octatrienyl (C8), etc.Unless otherwise specified, each example alkenyl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted alkenyl") or substituted ("substituted alkenyl") with one or more substituents, e.g., 1-5 substituents, 1-3 substituents, or 1 substituent. In certain embodiments, an alkenyl group is an unsubstituted C2-10 alkenyl. In certain embodiments, an alkenyl group is a substituted C2-10 alkenyl.

[0040] "Alkynyl" refers to a straight chain or branched hydrocarbon group having 2 to 20 carbon atoms, one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 carbon-carbon triple bonds), and optionally one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 carbon-carbon double bonds) ("C2-20 alkynyl"). In certain embodiments, the alkynyl does not contain any double bonds. In some embodiments, the alkynyl group has 2 to 10 carbon atoms ("C2-10 alkynyl"). In some embodiments, the alkynyl group has 2 to 9 carbon atoms ("C2-9 alkynyl"). In some embodiments, the alkynyl group has 2 to 8 carbon atoms ("C2-8 alkynyl"). In some embodiments, the alkynyl group has 2 to 7 carbon atoms ("C2-7 alkynyl"). In some embodiments, an alkynyl group has 2-6 carbon atoms ("C2-6 alkynyl"). In some embodiments, an alkynyl group has 2-5 carbon atoms ("C2-5 alkynyl"). In some embodiments, an alkynyl group has 2-4 carbon atoms ("C2-4 alkynyl"). In some embodiments, an alkynyl group has 2-3 carbon atoms ("C2-3 alkynyl"). In some embodiments, an alkynyl group has 2 carbon atoms ("C2 alkynyl"). One or more of the carbon-carbon triple bonds may be internal (such as 2-butynyl) or terminal (such as 1-butynyl). Examples of C2-4 alkynyl groups include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. Examples of C2-6 alkenyl groups include the C2-4 alkynyl groups mentioned above, as well as pentynyl (C5), hexynyl (C6), and the like. Further examples of alkynyl groups include heptynyl (C7), octynyl (C8), and the like. Unless otherwise specified, each example alkynyl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted alkynyl") or substituted ("substituted alkynyl") with one or more substituents, for example, 1-5 substituents, 1-3 substituents, or 1 substituent.In certain embodiments, the alkynyl group is unsubstituted C2-10 alkynyl. In certain embodiments, the alkynyl group is substituted C2-10 alkynyl.

[0041] "Aryl" refers to a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10 or 14 pi electrons shared in the cyclic arrangement) having 6-14 ring carbon atoms and zero heteroatoms in the aromatic ring system ("C6-14 aryl"). In some embodiments, an aryl group has a ring of 6 carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms ("C10 aryl"; e.g., naphthyl, such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms ("C14 aryl"; e.g., anthracyl). "Aryl" also includes ring systems in which an aryl ring is fused with one or more carbocyclyl or heterocyclyl groups, as defined above, where the radical or point of attachment is on the aryl ring, and in such cases the number of carbon atoms continues to represent the number of carbon atoms in the aryl ring system. Exemplary aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, and trinaphthalene. Particular aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl. Unless otherwise specified, each example aryl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted aryl") or substituted ("substituted aryl") with one or more substituents. In certain embodiments, the aryl group is unsubstituted C6-14 aryl. In certain embodiments, the aryl group is substituted C6-14 aryl.

[0042] "Heteroaryl" refers to a radical of a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 pi electrons shared in the cyclic arrangement) having ring carbon atoms and 1-4 heteroatoms in the aromatic ring system ("5-10 membered heteroaryl"), where each heteroatom is independently selected from nitrogen, oxygen and sulfur. In heteroaryl groups containing one or more nitrogen atoms, the point of attachment may be a carbon atom or a nitrogen atom, if valence permits. Heteroaryl bicyclic ring systems may contain one or more heteroatoms in one or both rings. "Heteroaryl" includes ring systems in which a heteroaryl ring as defined above is fused with one or more carbocyclyl or heterocyclyl groups, where the point of attachment is on the heteroaryl ring, and in such cases the number of ring members continues to represent the number of ring members in the heteroaryl ring system. "Heteroaryl" also includes ring systems in which a heteroaryl ring as defined above is fused with one or more aryl groups. Here, the point of attachment is on either the aryl ring or the heteroaryl ring, and in such cases the number of ring members represents the number of ring members in the fused (aryl / heteroaryl) ring system. Bicyclic heteroaryl groups in which one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, etc.) can have the point of attachment on either ring, i.e., either the ring with a heteroatom (e.g., 2-indolyl) or the ring without a heteroatom (e.g., 5-indolyl). In some embodiments, the heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms in the aromatic ring system ("5-10 membered heteroaryl"), where each heteroatom is independently selected from nitrogen, oxygen, and sulfur. In some embodiments, the heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms in the aromatic ring system ("5-8 membered heteroaryl"), where each heteroatom is independently selected from nitrogen, oxygen, and sulfur. In some embodiments, the heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms in the aromatic ring system (a "5-6 membered heteroaryl").wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise indicated, each exemplary heteroaryl group is independently optionally substituted, i.e., unsubstituted ("unsubstituted heteroaryl") or substituted ("substituted heteroaryl") with one or more substituents. In certain embodiments, the heteroaryl group is an unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is a substituted 5-14 membered heteroaryl. Exemplary 5 membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azepinyl, oxepinyl, and thiepinyl.Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzoxadiazolyl, benzothiazolyl, benzoisothiazolyl, benzothiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.

[0043] "Carbocyclyl" or "carbocyclic" refers to the radical of a non-aromatic cyclic hydrocarbon group having 3 to 10 ring carbon atoms ("C3-10 carbocyclyl") and zero heteroatoms in the non-aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms ("C3-8 carbocyclyl"). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms ("C3-6 carbocyclyl"). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms ("C3-6 carbocyclyl"). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms ("C5-10 carbocyclyl"). Exemplary C3-6 carbocyclyl groups include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), etc. Exemplary C3-8 carbocyclyl groups include, but are not limited to, the above C3-6 carbocyclic groups, as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptyl (C7), bicyclo[2.2.2]octyl (C8), etc. Exemplary C3-10 carbocyclyl groups include, but are not limited to, the C3-8 carbocyclyl groups listed above, as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-1H-indenyl (C9), decahydronaphthyl (C10), spiro[4.5]decyl (C10), and the like. As illustrated by the examples above, in some embodiments, the carbocyclyl group is a carbocyclyl group that includes a monocyclic ring ("monocyclic carbocyclyl") or a fused, bridged, or spiro ring system, such as a bicyclic ring system ("bicyclic carbocyclyl"). The carbocyclyl group can be a saturated or partially unsaturated carbocyclyl group."Carbocyclyl" also includes ring systems in which a carbocyclyl ring as described above is fused to one or more aryl or heteroaryl groups, where the point of attachment is on the carbocyclyl ring, and in such cases the number of carbons continues to represent the number of carbons in the carbocyclyl ring system. Unless otherwise specified, each carbocyclyl group is independently optionally substituted, i.e., unsubstituted "unsubstituted carbocyclyl" or substituted ("substituted carbocyclyl") with one or more substituents. In some embodiments, a carbocyclyl is an unsubstituted C3-10 carbocyclyl. In some embodiments, a carbocyclyl is a substituted C3-10 carbocyclyl. In some embodiments, a "carbocyclyl" is a monocyclic saturated carbocyclyl having 3 to 10 ring carbon atoms ("C3-10 cycloalkyl"). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ("C3-8 cycloalkyl"). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ("C3-6 cycloalkyl"). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms ("C5-6 cycloalkyl"). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms ("C5-10 cycloalkyl"). Examples of C5-6 cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C6). Examples of C3-6 cycloalkyl groups include the C5-6 cycloalkyl groups listed above, as well as cyclopropyl (C3) and cyclobutyl (C4). Examples of C3-8 cycloalkyl groups include the C3-6 cycloalkyl groups listed above, as well as cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each example cycloalkyl group is independently unsubstituted ("unsubstituted cycloalkyl") or substituted ("substituted cycloalkyl") with one or more substituents. In some embodiments, a cycloalkyl is an unsubstituted C3-10 cycloalkyl. In some embodiments, the cycloalkyl is a substituted C3-10 cycloalkyl.

[0044] "Heterocyclyl" or "heterocyclic" refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms ("3- to 10-membered heterocyclyl"). Here, each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon. In heterocyclic groups containing one or more nitrogen atoms, the point of attachment may be at a carbon atom or at a nitrogen atom, if valence permits. Heterocyclyl groups may be either monocyclic ("monocyclic heterocyclyl") or fused, bridged, or spiro ring systems, such as bicyclic systems ("bicyclic heterocyclyl"). Heterocyclyl groups may be saturated or partially unsaturated. Heterocyclyl bicyclic ring systems may contain one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems in which a heterocyclyl ring as defined above is fused to one or more carbocyclyl groups and the point of attachment is on the carbocyclyl or heterocyclyl ring, or a heterocyclyl ring as defined above is fused to one or more aryl or heteroaryl groups and the point of attachment is on the heterocyclyl ring. In such cases, the number of ring members continues to refer to the number of ring members in the heterocyclyl ring system. Unless otherwise indicated, each heterocyclyl instance is independently optionally substituted, i.e., unsubstituted ("unsubstituted heterocyclyl") or substituted ("substituted heterocyclyl") with one or more substituents. In certain embodiments, the heterocyclyl group is an unsubstituted 3-10 membered heterocyclyl. In certain embodiments, the heterocyclyl group is a substituted 3-10 membered heterocyclyl. In some embodiments, a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms ("5-10 membered heterocyclyl"), where each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon. In some embodiments, a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms ("5-8 membered heterocyclyl"), where each heteroatom is independently selected from nitrogen, oxygen, and sulfur.In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system ("5-6 membered heterocyclyl") having ring carbon atoms and 1-4 ring heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur. In some embodiments, a 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, a 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, a 5-6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.

[0045] "Hetero" when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group are replaced with a nitrogen, oxygen, or sulfur heteroatom. Hetero can apply to any of the above hydrocarbyls: for example, alkyl, such as heteroalkyl; cycloalkyl groups, such as heterocyclyl groups; aryl, such as heteroaryl; cycloalkenyl groups, such as cycloheteroalkenyl, etc.; the hydrocarbyl has 1-5 heteroatoms, particularly 1-3 heteroatoms.

[0046] "Alkoxy" refers to the group -OR, where R is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. Particular alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy. Particular alkoxy groups are lower alkoxy, i.e., those having 1 to 6 carbon atoms. Further particular alkoxy groups have 1 to 4 carbon atoms. Exemplary substituted alkoxy groups include, but are not limited to, the following: -O-(CH2) t (C6~C 10Aryl), -O-(CH2) t (5-10 membered heteroaryl), -O-(CH2) t (C3~C 10 cycloalkyl), and -O-(CH2) t (4-10 membered heterocyclyl); where t is an integer from 0 to 4. Optional substituted groups include any aryl, heteroaryl, cycloalkyl or heterocyclyl group present, which may itself be substituted with an unsubstituted C1-C4 alkyl group, a halo, an unsubstituted C1-C4 alkoxy group, an unsubstituted C1-C4 haloalkyl group, an unsubstituted C1-C4 hydroxyalkyl group, or an unsubstituted C1-C4 haloalkoxy group, or a hydroxy group.

[0047] "Carboxy" refers to -C(O)OH.

[0048] "Cyano" refers to -CN.

[0049] "Halo" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), and iodine (I) atoms. In certain embodiments, a halo group is either a fluorine or chlorine atom.

[0050] "Hydroxy" refers to --OH.

[0051] "Nitro" refers to -NO2.

[0052] [Other definitions] The term "pharmaceutically acceptable salts" refers to those salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic reactions, etc., commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1-19. Pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of amino groups. The salts of said amino groups are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art, such as ion exchange. Other pharma- ceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, and 2-hydroxy-ethanesulfonate. , lactobionate, lactate, laurate, laurin sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, etc. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N+(C1-4 alkyl)4 salts.Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Further pharma-ceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations, formed where appropriate with counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkylsulfonates, and arylsulfonates. [Brief description of the drawings]

[0053] [Figure 1] FIG. 1 is a graph showing the time course of changes in plasma and brain controls. [Diagram 2] FIG. 2 is a graph showing the time course of KH022 in plasma and brain. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0054] In order to better illustrate the technical concept of the present invention, the present invention provides some compound synthesis or biological examples, but not to further limit the protection scope of the present invention.

[0055] 〔material and method〕 The compounds provided herein can be prepared from readily available starting materials using the following general methods and procedures.Under typical or preferred process conditions (i.e., reaction temperature, time, molar ratio of reactants, solvent, pressure, etc.), it is understood that other process conditions can also be used unless otherwise stated.Optimal reaction conditions may vary depending on the specific reactants or solvents used.However, such conditions can be determined by those skilled in the art based on routine optimization.

[0056] Additionally, it will be apparent to one skilled in the art that conventional protecting groups may be required to prevent undesired reactions of certain functional groups. It is known in the art how to select an appropriate protecting group for a particular functional group, and appropriate conditions for protection and deprotection.

[0057] The compounds provided herein can be isolated and purified by known standard methods, including but not limited to recrystallization, column chromatography, HPLC, or supercritical fluid chromatography (SFC).Details of the preparation of representative pyrazoles herein are provided in the following reaction schemes.

[0058] The compounds provided herein can be prepared according to methods described in the art using the appropriate reagents, starting materials and purification methods known to those of skill in the art.

[0059] Example 1: Synthesis of compound KH001

[0060] [ka]

[0061] Compound KHC-2: KCN (600.0 g, 9.2 mol), acetic acid (640 mL) were added to a solution of compound KHC-1 (100.0 g, 0.3 mol) in methanol (4 L) and the reaction was stirred at room temperature (RT) overnight. The reaction solution was poured into water and extracted with ethyl acetate (EA). The organic phase was dried over anhydrous sodium sulfate and concentrated under vacuum to obtain the crude product. This was dissolved in acetic acid (2.5 L). Platinum dioxide (24.0 g, 0.1 mol) was added to the reaction solution and hydrogenation was carried out with H2 gas. When TLC showed the reaction was complete, the reaction solution was filtered, then the filtrate was concentrated to about 200 mL and diluted with ice water (2.4 L). Aqueous NaNO2 (46.0 g, 0.7 mol) was slowly added dropwise to the mixture, after which the mixture was stirred at room temperature for 15 h and extracted with EA. The combined organic layers were washed with brine, dried, concentrated and purified by silica gel column flash chromatography to give KHC-2 (57.3 g, 55% yield).

[0062] Compound KHC-3: Ethynylmagnesium bromide (395 mL, 0.5 M) was added dropwise to a solution of compound KHC-2 (57.3 g, 164.5 mmol) in THF (1 L) at -78 °C under N2 atmosphere, then gradually warmed to RT and stirred at RT overnight. Saturated aqueous NH4Cl was slowly added to the above mixture, followed by extraction with EA. The organic phase was washed with brine, dried over anhydrous Na2SO4, concentrated, and the resulting crude product was purified by silica gel column flash chromatography to give compound KHC-3 (33.7 g, 55% yield).

[0063] Compound KHC-4: Compound KHC-3 (33.7 g, 90.5 mmol) was dissolved in a mixed solvent of acetic acid (200 mL) and water (20 mL), and then heated to reflux by adding Dowex-50 (10.0 g). After the reaction was completed, it was cooled to RT, and the resin was filtered and washed with EA. The filtrate was neutralized with 40% aqueous NaOH solution, and the organic layer was washed with saturated brine, dried over anhydrous Na2SO4, concentrated, and the obtained crude product was purified by silica gel column flash chromatography to obtain compound KHC-4 (23.6 g, 70% yield).

[0064] Compound KHC-5: Compound KHC-4 (23.6 g, 63.3 mmol) and palladium black (1.2 g) in THF (200 mL) were stirred at RT overnight, then hydrogenated with H2 gas. The mixture was filtered through a pad of Celite, washed with EA, and the filtrate was concentrated in vacuo to give the crude compound. The crude compound was recrystallized from acetone to give compound KHC-5 (19.0 g, 80% yield).

[0065] Compound KH001: Aqueous NaOH (50 mL, 1M) was slowly added to a solution of compound KHC-5 (19.0 g, 50.8 mmol) in THF (200 ml) and stirred overnight at RT. The pH of the reaction was adjusted with dilute hydrochloric acid, followed by extraction with EA. The organic phase was washed with brine, dried over anhydrous Na2SO4, and concentrated to give the crude product. The crude product was purified by silica gel column flash chromatography to give compound KH001 (13.5 g, 80% yield). 1 H NMR(400MHz,CDCl3), δ 4. 06(s,1H), 2.32-2.28(dd,1H), 2.15(s,3H),1.84-1.77(m,2H), 1.74-1.61(m,5H), 1.61-1. 54(m,3H), 1.48-1.46(m,1H), 1.33-1.14(m,10H), 1.02-0.95(m,1H), 0.93(s,3H), 0.85-0.79(m,3H), 0.75(s,3H).

[0066] Example 2: Synthesis of compound KH002

[0067] [ka]

[0068] Compound KHC-6: Compound KH001 (1.5 g, 4.5 mmol) synthesized in Example 1 was dissolved in CH3OH (40 mL) until the solution became clear, and then the solution was cooled to 5° C. in ice water. Bromine (1.5 g, 9.2 mmol) was then added dropwise to the cooled solution. The ice bath was removed and the reaction was carried out at RT for 4 h, during which the reaction solution turned from orange to pale yellow. When TLC monitoring of the reaction showed that the reaction was complete, water (30 mL) was added to the reaction solution and extraction was carried out with EA (2×35 mL). The combined organic layer was washed with saturated brine and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain a pale yellow crude solid. The crude solid was purified by silica gel column flash chromatography (eluent: CH2Cl2) to obtain a white solid (1.0 g, 56.7% yield).

[0069] Compound KH002: Compound KHC-6 (80 mg, 0.2 mmol) was dissolved in THF (5 mL) until the solution was clear, then K2CO3 (83 mg, 0.6 mmol) and 4-cyanopyrazole (56 mg, 0.6 mmol) were added. The reaction was carried out at room temperature overnight. After TLC monitoring of the reaction showed the reaction was completed, the reaction was washed with 10 mL of water and extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated brine and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain a light yellow crude solid. The crude solid was purified by silica gel column flash chromatography (eluent: CH2Cl2 / CH3OH=100:1) and then recrystallized (EA / PE=1:10) to obtain a white solid (36 mg, 42.5% yield). 1H NMR (400 MHz, CDCl3) δ 7.82 (s, 1H), 7.80 (s, 1H), 5.06-4.93 (m, 2H), 4.05-4.04 (m, 1H), 2.32 (dd, 1H), 1.88-1.83 (m, 2H), 1.79-1.66 (m, 4H), 1.64-1.58 (m,2H), 1.54-1.44 (m, 4H), 1.39-1.13 (m, 9H), 1.04-0.97 (m, 1H), 0.94 (s, 3H), 0.85-0.75 (m, 3H), 0.74 (s, 3H).

[0070] Example 3: Synthesis of compound KH003

[0071] [ka]

[0072] Compound KH003: Compound KHC-6 (50 mg, 0.1 mmol) was dissolved in THF (5 mL) until the solution was clear, then K2CO3 (50 mg, 0.3 mmol) and 1H-triazole (25 mg, 0.3 mmol) were added. The reaction was carried out at room temperature overnight. After TLC monitoring of the reaction showed the reaction was completed, the reaction was washed with 10 mL of water and extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated brine and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain a light yellow crude solid. The crude solid was purified by silica gel column flash chromatography (eluent: CH2Cl2 / CH3OH=150:1) and then recrystallized (EA / PE=1:10) to obtain a white solid (17 mg, 35.5% yield). 1 H NMR (400 MHz, CDCl3) δ 7.76 (s, 1H), 7.60 (s, 1H), 5.31-5.17 (m, 2H), 4.06-4.05 (m, 1H), 2.37 (d, 1H), 1.87-1.61 (m, 8H), 1.52-1.10 (m, 13H), 1.04-0.98 (m, 1H), 0.95 (s, 3H), 0.92-0.79 (m, 3H), 0.74 (s, 3H).

[0073] Example 4: Synthesis of compounds KH004 and KH005

[0074] [ka]

[0075] Compounds KH004 and KH005: Compound KHC-6 (103 mg, 0.2 mmol) was dissolved in CH3CN (15 mL) until the solution was clear, then Cs2CO3 (244 mg, 0.7 mmol) and 1H-tetrazolium (53 mg, 0.7 mmol) were added. The reaction was carried out at room temperature. When TLC monitoring of the reaction showed the reaction was complete, the reaction was washed with 10 mL of water and extracted with EA (2 x 25 mL). The combined organic layer was washed with saturated brine and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain a light yellow crude solid. The crude solid was purified by silica gel column flash chromatography (eluent: CH2Cl2 / CH3OH = 150:1 to 90:1) to obtain two compounds. These two compounds were each recrystallized (EA / PE=1:10) to give white solid 1 (24 mg, 24.0% yield) and white solid 2 (36 mg, 36.0% yield). White solid 1 (KH004): 1H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H), 5.50 (s, 2H), 4.06-4.05 (m, 1H), 2.35 (dd, 1H), 1.92-1.81 (m, 3H), 1.74-1.68 (m, 3H), 1.64-1.57 (m,4H), 1.46-1.11 (m, 10H), 1.05-0.98 (m, 2H), 0.96 (s, 3H),0.88-0.78 (m, 3H), 0.75 (s, 3H). White solid 2 (KH005): 1 H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 5.38 -5.23 (m, 2H), 4.06-4.05 (m, 1H), 2.41 (dd, 1H), 2.28 (dd, 1H), 1.91-1.72 (m, 4H), 1.68-1.51 (m, 7H), 1.47-1.11 (m, 10H), 1.06-0.99 (m, 1H), 0.95 (s, 3H), 0.91-0.78 (m, 3H), 0.75 (s, 3H).

[0076] [Example 5: Synthesis of compound KH006]

[0077]

change

[0078] Compound KH006: Compound KHC-6 (50 mg, 0.1 mmol) was dissolved in CH3CN (8 mL) until the solution was clear, then Cs2CO3 (117 mg, 0.3 mmol) and 1H-pyrazole (24 mg, 0.3 mmol) were added. The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, the reaction was washed with 10 mL of water and extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated brine and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain a light yellow crude solid. The crude solid was purified by flash chromatography on a silica gel column (eluent: CH2Cl2 / CH3OH=100:1) and recrystallized (EA / PE=1:10) to obtain a white solid (24 mg, 50.2% yield). 1 H NMR (400 MHz, CDCl3) δ 7.56 (d, 1H), 7.39 (d, 1H), 6.34 (s, 1H), 5.03-4.92 (m, 2H), 4.05-4.04 (m, 1H), 2.28 (dd, 1H), 1.86-1.73 (m, 4H), 1.71-1.61 (m, 3H), 1. 60-1.49 (m,4H), 1.48-1.09 (m, 10H), 1.03-0.97 (m, 1H), 0.95 (s, 3H), 0.81-0.76 ( m, 3H), 0.74 (s, 3H).

[0079] Example 6: Synthesis of compound KH007

[0080] [ka]

[0081] Compound KH007: Compound KHC-6 (150 mg, 0.3 mmol) was dissolved in THF (10 mL), followed by the addition of K2CO3 (152 mg, 1.1 mmol) and 1H-imidazole (75 mg, 1.1 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction solution and extraction was carried out with EA (2 x 20 mL). The combined organic layer was washed with saturated brine and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain a pale yellow crude solid. The crude solid was purified by silica gel column flash chromatography (eluent: CH2Cl2 / CH3OH = 30:1) and then recrystallized (EA) to obtain a white solid (35 mg, 24.1% yield). 1 H NMR (400 MHz, CDCl3) δ 7.47 (s, 1H), 7.11 (s, 1H), 6.85 (s, 1H), 4.74(d, 2H), 4.06-4.05 (m, 1H), 2.30 (dd, 1H),1.88-1.68 (m, 4H), 1.64-1.56 (m, 3H), 1.52-1.45 (m,4H), 1.40-1.11 (m, 10H), 1.04-0.97 (m, 1H), 0.95 (s, 3H), 0.83-0.77 (m, 3H), 0.75 (s, 3H).

[0082] Example 7: Synthesis of compound KH008

[0083] [ka]

[0084] Compound KH008: Compound KHC-6 (100 mg, 0.2 mmol) was dissolved in THF (10 mL), followed by the addition of K2CO3 (97 mg, 0.7 mmol) and 3-cyanopyrazole (68 mg, 0.7 mmol). The reaction was carried out at 70° C. for more than 2 h. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction solution and extraction was carried out with EA (2×20 mL). The combined organic layer was washed with saturated brine and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain a pale yellow crude solid. The crude solid was purified by TLC (eluent: PE / acetone=3:1) and then recrystallized (CH3CN) to obtain a white solid (20 mg, 19.4% yield). 1 H NMR (400 MHz, CDCl3) δ 7.44 (d, 1H), 6.72 (d, 1H), 6.34 (s, 1H), 5.00 (q, 2H), 4.06-4.05 (m, 1H), 2.32 (dd, 1H), 1.88-1.68 (m, 4H), 1.63-1.60 (m, 3H), 1.50-1.45 (m,4H), 1.41-1.11 (m, 10H), 1.04-0.97 (m, 1H), 0.95 (s, 3H), 0.87-0.79 (m, 3H), 0.75 (s, 3H).

[0085] Example 8: Synthesis of compound KH009

[0086] [ka]

[0087] Compound KH009: Compound KHC-6 (50 mg, 0.1 mmol) was clearly dissolved in CH3CN (5 mL), and then Cs2CO3 (120 mg, 0.3 mmol) and 1H-indole (68 mg, 0.7 mmol) were added. The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed that the reaction was completed, water (10 mL) was added to the reaction solution and extraction was carried out with EA (2 x 20 mL). The combined organic layer was washed with saturated brine and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain a pale yellow crude solid. The crude solid was purified by TLC (eluent: CH2Cl2 / EA = 10:1) to obtain a pale yellow solid (34 mg, 62.4% yield). 1 H NMR (400 MHz, CDCl3) δ 7.65-7.63 (m, 1H), 7.21-7.18 (m, 1H), 7.13-7.10 (m, 2H), 7.01-7.00 (m, 1H), 6.57 (d, 1H), 4.83 (d, 2H), 4.06-4.05 (m, 1H), 2.30 (dd, 1H), 1.82-1.72 (m, 4H), 1.64-1.61 (m, 3H), 1.51-1.45 (m,4H), 1.41-1.11 (m, 10H),1.01-0.96 (m, 1H), 0.96 (s, 3H), 0.92-0.77 (m, 3H), 0.74 (s, 3H).

[0088] Example 9: Synthesis of compound KH010

[0089] [ka]

[0090] Compound KH010: Compound KHC-6 (100 mg, 0.2 mmol) was dissolved in CH3CN (5 mL), followed by the addition of K2CO3 (101 mg, 0.7 mmol) and 4-(trifluoromethyl)-1H-pyrazole (35 mg, 0.2 mmol). The reaction was carried out at 50°C for more than 2 h. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction solution and extraction was carried out with EA (2 x 20 mL). The combined organic layer was washed with saturated brine and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain a pale yellow crude solid. The crude solid was purified by silica gel column flash chromatography (eluent: PE / acetone = 7:1) and then recrystallized (CH3CN) to obtain a white solid (61 mg, 53.1% yield). 1 H NMR (400 MHz, CDCl3) δ 7.71 (d, 2H), 4.98 (q, 2H), 4.06-4.05 (m, 1H), 2.32 (dd, 1H), 1.87-1.68 (m, 4H), 1.64-1.57 (m, 3H), 1.52-1.45 (m,4H), 1.41-1.11 (m, 10H), 1.04-0.97 (m, 1H), 0.95 (s, 3H), 0.87-0.82 (m, 3H), 0.74 (s, 3H).

[0091] Example 10: Synthesis of compound KH011

[0092] [ka]

[0093] Compound KH011: Compound KHC-6 (50 mg, 0.1 mmol) was dissolved in CH3CN (5 mL), followed by the addition of Cs2CO3 (120 mg, 0.3 mmol) and 1H-indazole (43 mg, 0.3 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction solution and extraction was carried out with EA (2 x 20 mL). The combined organic layer was washed with saturated brine and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain a pale yellow crude solid. The crude solid was purified by TLC (eluent: PE / acetone = 3:1) and then recrystallized (CH3CN) to obtain a white solid (20 mg, 36.6% yield). 1 H NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 7.78 (d, 1H), 7.45-7.41 (m, 1H), 7.23-7.19 (m, 2H),5.31-5.20 (m, 2H), 4.06-4.05 (m, 1H), 2.35 (dd, 1H), 1.87-1.72 (m, 4H), 1.67-1.63 (m, 3H), 1.54-1.45 (m,4H), 1.42-1.14 (m, 10H), 1.01-0.98 (m, 1H), 0.96 (s, 3H), 0.93-0.78 (m, 3H), 0.75 (s, 3H).

[0094] Example 11: Synthesis of compound KH012

[0095] [ka]

[0096] Compound KH012: Compound KHC-6 (50 mg, 0.1 mmol) was dissolved in CH3CN (5 mL), followed by the addition of Cs2CO3 (120 mg, 0.3 mmol) and 1H-purine (44 mg, 0.3 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction solution, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated brine and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product as a pale yellow solid. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH = 20:1) and then recrystallized (CH3CN) to obtain a white solid (5 mg, 9.1% yield). 1 H NMR (400 MHz, CDCl3) δ 9.22 (s, 1H), 9.06(s, 1H), 8.25(s, 1H), 5.18 (q, 2H), 4.07-4.06 (m, 1H), 2.49 (dd, 1H), 1.93-1.72 (m, 4H), 1.68-1.65 (m, 3H), 1.58-1.45 (m,4H), 1.42-1.13 (m, 10H), 1.06-1.00 (m, 1H), 0.96 (s, 3H), 0.90-0.80 (m, 3H), 0.74 (s, 3H).

[0097] Example 12: Synthesis of compound KH013

[0098] [ka]

[0099] Compound KH013: Compound KHC-6 (80 mg, 0.2 mmol) was dissolved in CH3CN (8 mL), followed by the addition of Cs2CO3 (196 mg, 0.6 mmol) and 4-chloropyrazole (62 mg, 0.6 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, 15 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2 x 30 mL). The combined organic layer was washed with saturated brine and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain a light yellow crude solid. The crude solid was purified by silica gel column flash chromatography (eluent: CH2Cl2 / CH3OH=100:1), followed by recrystallization (EA / PE=1:10) to obtain a white solid (28 mg, 32.3% yield). 1 H NMR (400MHz, CDCl3) δ 7.46 (s, 1H), 7.38 (s, 1H), 4.96-4.83 (m, 2H), 4.06-4.05 (m, 1H),2.19 (dd, 1H), 1.86-1.71 (m, 4H), 1.64-1.55 (m, 3H), 1.51-1.45 (m,4H), 1.45-1.10 (m, 10H), 1.03-0.96 (m, 1H), 0.95 (s, 3H), 0.86-0.77 (m, 3H), 0.74 (s, 3H).

[0100] Example 13: Synthesis of compound KH014

[0101] [ka]

[0102] Compound KH014: Compound KHC-6 (60 mg, 0.15 mmol) was dissolved in DMF (5 mL), and then NaOH (1 mL, 1.0 mmol) was added. The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed that the reaction was completed, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=50:1) to obtain a white solid (12 mg, 22.92% yield). 1 H NMR (400 MHz, DMSO-d6) δ 4.94 - 4.89 (m, 1H), 4.18 (t, 1H), 4.06 - 4.02 (m, 2H), 3.80 (t, 1H), 2.27 (dd, 1H), 1.77 - 0.65 (m, 27H), 0.68 (s, 3H).

[0103] Example 14: Synthesis of compound KH015

[0104] [ka]

[0105] Compound KH015: Compound KHC-6 (60 mg, 0.15 mmol) was dissolved in CH3CN (5 mL), followed by the addition of Cs2CO3 (98 mg, 0.30 mmol) and 6-chloropurine (46 mg, 0.30 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH = 40:1) to obtain a white solid (39 mg, 53.61% yield). 1H NMR (400 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.37 (s, 1H), 5.41 (q, 2H), 4.20 (d, 1H), 3.79 (t, 1H), 2.56 (dd, 1H), 1.80 - 0.75 (m, 27H), 0.69 (s, 3H) Example 15: Synthesis of compound KH016

[0106] [ka]

[0107] Compound KH016: KHC-6 (60 mg, 0.15 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of Cs2CO3 (98 mg, 0.30 mmol) and 2-mercaptothiophene (17 mg, 0.30 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=40:1) to obtain a white solid (19 mg, 28.34% yield). 1 H NMR (400 MHz, CDCl3) δ 7.35 (d, 1H), 7.14 (d, 1H), 6.95 (dd, 1H), 4.04 (t, 1H), 3.62 (q, 2H), 2.45 (dd, 1H), 1.65 - 0.81 (m, 27H), 0.73 (s, 3H).

[0108] Example 16: Synthesis of compound KH017

[0109] [ka]

[0110] Compound KH017: KHC-6 (60 mg, 0.15 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of Cs2CO3 (98 mg, 0.30 mmol) and 6-methoxypurine (45 mg, 0.30 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=40:1) to obtain a white solid (46 mg, 63.76% yield). 1 H NMR (400 MHz, DMSO-d6) δ 8.57 (s, 1H), 8.32 (s, 1H), 5.37 (q, 2H), 4.20 (d, 1H), 3.91 (s, 3H), 3.79 (t, 1H), 2.53 (dd, 1H), 1.79 - 0.75 (m, 27H), 0.69 (s, 3H).

[0111] Example 17: Synthesis of compounds KH018 and KH019

[0112] [ka]

[0113] Compounds KH018 and KH019: KHC-6 (60 mg, 0.15 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of Cs2CO3 (98 mg, 0.30 mmol) and 5-methyl-1H-tetrazole (25 mg, 0.30 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=40:1) to obtain white solid KH6070053-1 (13 mg, 20.88%) and KH6070053-2 (27 mg, 43.37%) as white solid, respectively. 1 H NMR (400 MHz, CDCl3) δ 4.39 (s, 2H), 4.05 (t, 1H), 2.56 (s, 3H), 2.34 (dd, 1H), 1.92 - 0.76 (m, 27H), 0.74 (s, 3H). 1 H NMR (400 MHz, CDCl3) δ 5.15 (dd, 2H), 4.06 (t, 1H), 2.43 (s, 3H), 2.39 (dd, 1H), 1.95 - 0.78 (m, 27H), 0.75 (s, 3H).

[0114] Example 18: Synthesis of compound KH020

[0115] [ka]

[0116] Compound KH020: KHC-6 (60 mg, 0.15 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of Cs2CO3 (98 mg, 0.30 mmol) and 2-oxa-6-aza-spiro[3,3]heptane (30 mg, 0.30 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=40:1) to obtain a white solid (21 mg, 32.56% yield). 1 H NMR (400 MHz, CDCl3) δ 4.75 (s, 4H), 4.04 (t, 1H), 3.57 (dd, 4H), 3.40 (dd, 2H), 2.13 (dd, 1H), 1.90 - 0.75 (m, 27H), 0.73 (s, 3H).

[0117] Example 19: Synthesis of compound KH021

[0118] [ka]

[0119] Compound KHC-7: KH001 (0.70 g, 2.11 mmol) was dissolved in 100 mL of CHCl, and DMP (1.78 g, 4.20 mmol) was added in a batch. The reaction was carried out at room temperature overnight under N. When TLC monitoring of the reaction showed the reaction was complete, 40 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2×80 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous NaSO. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by flash chromatography on silica gel (eluent: PE / acetone=40:1→30:1) to obtain KHC-7 (0.62 g, 89.47% yield) as a white solid.

[0120] Compound KH021: FeCl3 (0.61 g, 3.75 mmol) and LiCl (0.34 g, 8.07 mmol) were mixed and added to a 100 mL three-neck flask under N2 atmosphere. Anhydrous THF (40 mL) was then added, the mixture was stirred at RT for 5 min, and cooled to -45°C. CH3MgBr (15.20 mL, 15.20 mmol) was then added dropwise, the mixture was stirred at -40°C for 15 min, and then compound KHC-7 (0.62 g, 1.88 mmol) dissolved in anhydrous THF was added dropwise. The reaction was heated to about -20°C and stirred for 2 h. When TLC monitoring of the reaction showed that the reaction was complete, the reaction solution was quenched with 40 mL of saturated aqueous NH4Cl solution, and the mixture was extracted with EA (2*80 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to give the crude product, which was purified by flash chromatography on silica gel (eluent: PE / acetone=40:1→35:1) to give a white solid KH021 (0.52 g, yield 78.50%). 1 H NMR (400 MHz, CDCl3) 2.29 (dd, 1H), 2.13 (s, 3H), 1.88 - 1.25 (m, 21H), 1.20 (s, 3H), 0.95 (s, 3H), 0.88 - 0.78 (m, 3H), 0.70 (s, 3H).

[0121] Example 20: Synthesis of compounds KH022 and KH023

[0122] [ka]

[0123] [ka]

[0124] Compounds KHC-8 and KHC-9: Compound KH021 (1.25 g, 3.60 mmol) was dissolved in 40 mL of methanol until clear, and then bromine (0.86 g, 5.40 mmol) was added dropwise. After 4 h reaction at room temperature, the reaction solution turned from orange to pale yellow, and TLC monitoring indicated the reaction was complete. The reaction mixture was added with 30 mL of water and extracted with EA (2×65 mL). The combined organic layer was washed with saturated sodium chloride and dried over anhydrous sodium sulfate. The solvent was distilled under reduced pressure to obtain a pale yellow crude solid. The crude solid was purified by flash chromatography on silica gel (eluted with dichloromethane) to obtain a white solid KHC-8 (0.93 g, 60.78%) and a white solid KHC-9 (0.36 g, 19.89%).

[0125] Compounds KH022 and KH023: Compound KHC-8 (100 mg, 0.24 mmol) was dissolved in 5 mL of acetonitrile until clear, and Cs2CO3 (234 mg, 0.72 mmol) and 1H-tetrazole (50 mg, 0.72 mmol) were added. The reaction was carried out at room temperature overnight. TLC monitoring showed that the reaction was complete. The reaction mixture was added with 10 mL of water and extracted with ethyl acetate (2×20 mL). The combined organic layer was washed with saturated sodium chloride and dried over anhydrous sodium sulfate. The solvent was distilled under reduced pressure to obtain the crude product. Purification was carried out using thin layer chromatography (eluted with dichloromethane / methanol=30:1) using thick silica gel preparative plate to obtain white solid KH022 (20 mg, 20.08%) and white solid KH023 (47 mg, 47.19%), respectively. 1 H NMR (400 MHz, CDCl3) δ 8.56 (s, 1H), 5.54 - 5.45 (m, 2H), 2.35 (dd, 1H), 1.89 - 1.25 (m, 21H), 1.20 (s, 3H), 0.95 (s, 3H), 0.88 - 0.80 (m, 3H), 0.72 (s, 3H). 1H NMR (400 MHz, CDCl3) δ 8.71 (s, 1H), 5.30 (dd, 2H), 2.35 (dd, 1H), 1.83 - 1.23 (m, 21H),1.20 (s, 3H), 0.95 (s, 3H), 0.87 - 0.78 (m, 3H), 0.72 (s, 3H).

[0126] Example 21: Synthesis of compound KH024

[0127] [ka]

[0128] Compound KH024: KHC-8 (60 mg, 0.14 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of Cs2CO3 (91 mg, 0.28 mmol) and 3-cyanopyrazole (26 mg, 0.28 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring showed the reaction was complete, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=40:1) to obtain a white solid KH024 (16 mg, 26.09%). 1 H NMR (400 MHz, CDCl3) 7.45 (d, 1H), 6.73 (d, 1H), 5.06 (q, 2H), 2.30 (dd, 1H), 1.86 - 1.23 (m, 21H), 1.20 (s, 3H), 0.95 (s, 3H), 0.87 - 0.77 (m, 3H), 0.72 (s, 3H).

[0129] Example 22: Synthesis of compound KH025

[0130] [ka]

[0131] Compound KH025: KHC-8 (100 mg, 0.24 mmol) was dissolved in 5 mL of DMSO, followed by the addition of Cs2CO3 (235 mg, 0.72 mmol) and 3-hydroxybenzisoxazole (97 mg, 0.72 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring showed the reaction was complete, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone=5:1) to obtain a white solid KH025 (70 mg, 60.76%). 1 H NMR (400 MHz, CDCl3) δ 7.72 (d, 1H), 7.58 - 7.49 (m, 1H), 7.42 (d, 1H), 7.29 (d, 1H), 5.11 - 4.95 (m, 2H), 2.35 (dd, 1H), 1.87 - 1.22 (m, 21H), 1.20 (s, 3H), 0.99 (s, 3H), 0.87 - 0.80 (m, 3H), 0.72 (s, 3H) Example 23: Synthesis of compound KH026

[0132] [ka]

[0133] Compound KH026: KHC-8 (53 mg, 0.12 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of K2CO3 (100 mg, 0.72 mmol) and 2-mercaptobenzoxazole (24 mg, 0.16 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring showed the reaction was complete, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone = 6:1) to obtain a white solid KH026 (30 mg, 50.40%). 1 H NMR (400 MHz, CDCl3) δ 7.55 (d, 1H), 7.42 (d, 1H), 7.34 - 7.24 (m, 2H), 4.33 (m, 2H), 2.54 (dd, 1H), 1.83 - 1.23 (m, 21H), 1.18 (s, 3H), 0.94 (s, 3H), 0.85 - 0.78 (m, 3H), 0.70 (s, 3H).

[0134] Example 24: Synthesis of compound KH027

[0135] [ka]

[0136] Compound KH027: KHC-9 (110 mg, 0.22 mmol) was dissolved in 10 mL of CH3CN, followed by the addition of Cs2CO3 (215 mg, 0.66 mmol) and 4-cyanopyrazole (61 mg, 0.66 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring showed the reaction was complete, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=6:1) to obtain a white solid KH027 (76 mg, 65.30%). 1 H NMR (400 MHz, CDCl3) δ 8.23 ​​(s, 1H), 8.13 (s, 1H), 7.92 (s, 1H), 7.83 (s, 1H), 7.03 (s, 1H), 2.11 (dd, 1H), 1.83 - 1.23 (m, 21H), 1.20 (s, 3H), 0.91 (s, 3H), 0.82 - 0.75 (m, 3H), 0.70 (s, 3H).

[0137] Example 25: Synthesis of compound KH028

[0138] [ka]

[0139] Compound KH028: KHC-8 (70 mg, 0.16 mmol) was dissolved in 8 mL of DMSO, followed by the addition of Cs2CO3 (160 mg, 0.49 mmol) and 2-hydroxybenzoxazole (66 mg, 0.49 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring showed the reaction was complete, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=60:1) to obtain a white solid KH028 (55 mg, 71.61%). 1 H NMR (400 MHz, CDCl3) δ 7.24 - 7.18 (m, 1H), 7.17 - 7.06 (m, 2H), 6.75 - 6.64 (m, 1H), 4.58 (dd, 2H), 2.38 (dd, 1H), 1.92 - 1.22 (m, 21H), 1.20 (s, 3H), 0.97 (s, 3H), 0.89 - 0.78 (m, 3H), 0.72 (s, 3H).

[0140] Example 26: Synthesis of compound KH029

[0141] [ka]

[0142] Compound KH029: KHC-8 (60 mg, 0.14 mmol) was dissolved in 5 mL of DMSO, followed by the addition of Cs2CO3 (138 mg, 0.42 mmol) and 8-methyl-4-hydroxyquinazoline (68 mg, 0.42 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring showed the reaction was complete, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=60:1) to obtain a white solid KH029 (50 mg, 70.72%). 1 H NMR (400 MHz, CDCl3) δ 8.13 (d, 1H), 7.90 (s, 1H), 7.61 (d, 1H), 7.39 (t, 1H), 4.81 (s, 2H), 2.63 (s, 3H), 2.43 (dd, 1H), 1.88 - 1.22 (m, 21H), 1.20 (s, 3H), 0.97 (s, 3H), 0.90 - 0.81 (m, 3H), 0.72 (s, 3H).

[0143] Example 27: Synthesis of compound KH030

[0144] [ka]

[0145] Compound KH030: KHC-8 (50 mg, 0.12 mmol) was dissolved in 5 mL of DMSO, followed by the addition of Cs2CO3 (78 mg, 0.24 mmol) and 3-hydroxy-4-methyl-5-methoxy-4H-1,2,4-triazole (31 mg, 0.24 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring showed the reaction was complete, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone=4:1) to obtain a white solid KH030 (20 mg, 35.16%). 1 H NMR (400 MHz, CDCl3) δ 4.47 (q, 2H), 3.93 (s, 3H), 3.12 (s, 3H), 2.28 (dd, 1H), 1.86 - 1.22 (m, 21H), 1.19 (s, 3H), 0.94 (s, 3H), 0.85 - 0.78 (m, 3H), 0.70 (s, 3H).

[0146] Example 28: Synthesis of compound KH031

[0147] [ka]

[0148] Compound KH031: KHC-8 (60 mg, 0.14 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of K2CO3 (58 mg, 0.42 mmol) and 1-methyl-5-mercapto-1H-tetrazole (68 mg, 0.42 mmol). The reaction was carried out at room temperature. When TLC monitoring showed the reaction was complete, 10 mL of water was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone = 4:1) to obtain a white solid KH031 (50 mg, 77.47%). 1 H NMR (400 MHz, CDCl3) 4.40 (dd, 2H), 3.97 (s, 3H), 2.47 (dd, 1H), 1.88 - 1.22 (m, 21H), 1.19 (s, 3H), 0.93 (s, 3H), 0.87 - 0.79 (m, 3H), 0.71 (s, 3H).

[0149] Example 29: Synthesis of compound KH032

[0150] [ka]

[0151] Compound KH032: KHC-8 (50 mg, 0.12 mmol) was dissolved in 5 mL of DMSO, followed by the addition of K2CO3 (50 mg, 0.36 mmol) and 1-hydroxy-1H-imidazole (30 mg, 0.36 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone = 2:1) to obtain a white solid KH032 (11 mg, 21.37%). 1 H NMR (400 MHz, CDCl3) δ 9.26 (s, 1H), 6.32 (s, 1H), 6.17 (s, 1H), 4.53 - 4.32 (m, 2H), 2.31 (dd, 1H), 1.86 - 1.25 (m, 21H), 1.21 (s, 3H), 0.95 (s, 3H), 0.88 - 0.78 (m, 3H), 0.71 (s, 3H).

[0152] Example 30: Synthesis of compound KH033

[0153] [ka]

[0154] Compound KH033: KHC-8 (60 mg, 0.14 mmol) was dissolved in 5 mL of DMSO, followed by the addition of Cs2CO3 (138 mg, 0.42 mmol) and 2-hydroxyquinoline (61 mg, 0.42 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture, and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone=4:1) to obtain a white solid KH033 (15 mg, 21.87%). 1 H NMR (400 MHz, CDCl3) δ 8.05 (d, 1H), 7.75 (dd, 2H), 7.61 (t, 1H), 7.39 (t, 1H), 7.05 (d, 1H), 5.15 (s, 2H), 2.43 (dd, 1H), 1.98 - 1.23 (m, 21H), 1.21 (s, 3H), 0.97 (s, 3H), 0.91 - 0.78 (m, 3H), 0.74 (s, 3H).

[0155] Example 31: Synthesis of compound KH034

[0156] [ka]

[0157] Compound KH034: KHC-8 (60 mg, 0.14 mmol) was dissolved in 5 mL of DMSO, followed by the addition of K2CO3 (58 mg, 0.42 mmol) and 3-hydroxy-1H-1,2,4-triazole (36 mg, 0.42 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=40:1) to obtain a white solid KH034 (40 mg, 66.45%). 1 H NMR (400 MHz, CDCl3) δ 9.30 (s, 1H), 7.42 (s, 1H), 4.47 (q, 2H), 2.33 (dd, 1H), 1.87 - 1.25 (m, 21H), 1.20 (s, 3H), 0.95 (s, 3H), 0.87 - 0.79 (m, 3H), 0.71 (s, 3H).

[0158] Example 32: Synthesis of compound KH035

[0159] [ka]

[0160] Compound KH035: KHC-8 (80 mg, 0.19 mmol) was dissolved in 6 mL of DMSO, followed by the addition of Cs2CO3 (184 mg, 0.56 mmol) and 8-fluoro-4-hydroxyquinazoline (92 mg, 0.56 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture, and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone=2:1) ​​to obtain a white solid KH035 (65 mg, 67.21%). 1 H NMR (400 MHz, CDCl3) δ 8.06 (d, 1H), 7.88 (s, 1H), 7.55 - 7.40 (m, 2H), 4.79 (m, 2H), 2.43 (dd, 1H), 1.88 - 1.22 (m, 21H), 1.21 (s, 3H), 0.96 (s, 3H), 0.90 - 0.81 (m, 3H), 0.72 (s, 3H).

[0161] Example 33: Synthesis of compound KH036

[0162] [ka]

[0163] Compound KH036: KHC-8 (60 mg, 0.14 mmol) was dissolved in 5 mL of DMSO, followed by the addition of K2CO3 (58 mg, 0.42 mmol) and 6-fluoropyridine[3,4-d]pyrimidin-4-one (69 mg, 0.42 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=40:1) to obtain a white solid KH036 (40 mg, 56.02%). 1 H NMR (400 MHz, CDCl3) δ 8.82 (s, 1H), 7.80 (s, 1H), 7.66 (d, 1H), 4.80 (q, 2H), 2.43 (dd, 1H), 1.89 - 1.23 (m, 21H), 1.20 (s, 3H), 0.95 (s, 3H), 0.90 - 0.80 (m, 3H), 0.71 (s, 3H).

[0164] Example 34: Synthesis of compound KH037

[0165] [ka]

[0166] Compound KH037: KHC-8 (60 mg, 0.14 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of K2CO3 (58 mg, 0.42 mmol) and 4-methyl-4H-3-mercapto-1,2,4-triazole (49 mg, 0.42 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed that the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone = 3:2) to obtain a white solid KH037 (53 mg, 82.30%). 1 H NMR (400 MHz, CDCl3) δ 8.16 (s, 1H), 4.34 (dd, 2H), 3.65 (s, 3H), 2.45 (dd, 1H), 1.88 - 1.22 (m, 21H), 1.19 (s, 3H), 0.91 (s, 3H), 0.87 - 0.79 (m, 3H), 0.70 (s, 3H).

[0167] Example 35: Synthesis of compound KH038

[0168] [ka]

[0169] Compound KH038: KHC-8 (60 mg, 0.14 mmol) was dissolved in 5 mL of DMSO, followed by the addition of Cs2CO3 (138 mg, 0.42 mmol) and 3-hydroxyisoxazole (36 mg, 0.42 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed that the reaction was complete, water (10 mL) was added to the reaction mixture, and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone=15:1) to obtain a white solid KH038 (39 mg, 65.00%). 1 H NMR (300 MHz, CDCl3) δ 8.12 (d, 1H), 6.06 (d, 1H), 4.87 (s, 2H), 2.29 (dd, 1H), 1.90 - 1.22 (m, 21H), 1.20 (s, 3H), 0.97 (s, 3H), 0.90 - 0.74 (m, 3H), 0.71 (s, 3H).

[0170] Example 36: Synthesis of compound KH039

[0171] [ka]

[0172] Compound KH039: KHC-8 (75 mg, 0.18 mmol) was dissolved in 5 ml of CH3CN, followed by the addition of Cs2CO3 (171 mg, 0.53 mmol) and 5-phenyltetrazole (77 mg, 0.53 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone = 3:1) to obtain a white solid KH039 (79 mg, 89.39%). 1 H NMR (400 MHz, CDCl3) δ 8.19 - 8.07 (m, 2H), 7.55 - 7.42 (m, 3H), 5.54 - 5.40 (m, 2H), 2.37 (dd, 1H), 1.92 - 1.23 (m, 21H), 1.21 (s, 3H), 0.97 (s, 3H), 0.90 - 0.78 (m, 3H), 0.73 (s, 3H).

[0173] Example 37: Synthesis of compound KH040

[0174] [ka]

[0175] Compound KH040: KHC-8 (60 mg, 0.14 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of Cs2CO3 (91 mg, 0.28 mmol) and 4-cyanopyrazole (26 mg, 0.28 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH = 40:1) to obtain a white solid KH040 (16 mg, 26.09%). 1 H NMR (400 MHz, CDCl3) δ 7.82 (s, 1H), 7.81 (s, 1H), 5.00 (q, 2H), 2.32 (dd, 1H), 1.88 - 1.22 (m, 21H), 1.20 (s, 3H), 0.94 (s, 3H), 0.87 - 0.79 (m, 3H), 0.71 (s, 3H).

[0176] Example 38: Synthesis of compound KH041

[0177] [ka]

[0178] Compound KH041: KHC-8 (70 mg, 0.16 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of Cs2CO3 (160 mg, 0.49 mmol) and 2-mercaptothiophenone (57 mg, 0.49 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / PE=1:1) to obtain a grey solid KH041 (27 mg, 35.53%). 1 H NMR (400 MHz, CDCl3) δ 7.35 (dd, 1H), 7.14 (dd, 1H), 6.95 (dd, 1H), 3.62 (dd, 2H), 1.90 - 1. 21 (m, 21H), 1.20 (s, 3H), 0.90 (s, 3H), 0.84 - 0.74 (m, 3H), 0.70 (s, 3H).

[0179] Example 39: Synthesis of compound KH042

[0180] [ka]

[0181] Compound KH042: KHC-8 (150 mg, 0.35 mmol) was dissolved in water (15 mL) and acetone (30 mL), followed by the addition of K2CO3 (49 mg, 0.35 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture, and the mixture was extracted with EA (2 x 30 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=50:1) to obtain a white solid KH042 (21 mg, 16.54%). 1 H NMR (400 MHz, DMSO-d6) δ 4.92 (t, 1H), 4.06 - 4.04 (m, 2H), 3.85 (t, 1H), 2.27 (dd, 1H), 1.82 - 1.10 (m, 21H), 1.05 (s, 3H), 0.87 (s, 3H), 0.85 - 0.70 (m, 3H), 0.65 (s, 3H).

[0182] Example 39: Synthesis of compounds KH043 and KH044

[0183] [ka]

[0184] Compounds KH043 and KH044: KHC-8 (60 mg, 0.14 mmol) was dissolved in 5 ml of CH3CN, followed by the addition of Cs2CO3 (91 mg, 0.28 mmol) and 1H-triazole (15 mg, 0.21 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=40:1) to obtain white solid KH6070100-1 (12 mg, 20.70%) and white solid KH6070100-2 (27 mg, 46.58%), respectively. 1 H NMR (400 MHz, CDCl3) δ 7.68 (s, 2H), 5.34 - 5.20 (m, 2H), 2.25 (dd, 1H), 1.88 - 1.23 (m, 21H), 1.20 (s, 3H), 0.95 (s, 3H), 0.89 - 0.79 (m, 3H), 0.71 (s, 3H). 1 H NMR (400 MHz, CDCl3) δ 7.76 (s, 1H), 7.61 (s, 1H), 5.25 (dd, 2H), 2.37 (dd, 1H), 1.86 - 1.22 (m, 21H), 1.20 (s, 3H), 0.94 (s, 3H), 0.86 - 0.76 (m, 3H), 0.71 (s, 3H).

[0185] Example 40: Synthesis of compound KH045 Compound KHC-11: Compound KHC-10 (150.0 g, 183.8 mmol) was dissolved in THF (500 mL) and 10% Pd / C (6.0 g) was added to the solution. The solution was then hydrogenated under H2 gas and stirred at room temperature for 24 hours, after which it was filtered. The filtrate was concentrated under vacuum to obtain a crude product. The crude product was then stirred with a solution (eluent: PE:acetone = 1:1) to obtain compound KHC-11 (150.0 g, yield 99.26%).

[0186] Compound KHC-12: KHC-11 (150.0 g, 547.4 mmol) was dissolved in 1000 mL of CHOH, and then I2 (14.0 g, 54.8 mmol) was added to the solution. The solution was heated to 60° C. and kept stirring for 12 h. The solution was then concentrated under vacuum, and the residue was purified by silica gel column flash chromatography (eluent: PE:EA=10:1) to obtain a white solid KHC-12 (130.0 g, 74.20%).

[0187] Compound KHC-13: KHC-12 (130.0 g, 406.2 mmol) was dissolved in 1000 ml of DMF, and t-BuOK (91.0 g, 812.4 mmol) and trimethyliodonium sulfide (165.8 g, 812.7 mmol) were added to the solution. The solution was kept stirring at room temperature under N2 gas for 12 h. Then, brine was added to the reaction mixture and the mixture was extracted with EA (3 x 1 L). The organic layers were combined and concentrated under vacuum to give a white solid KHC-13 (120.0 g, 88.50%).

[0188] Compound KHC-14: KHC-13 (120.0 g, 359.4 mmol) was dissolved in 900 mL of ethanol and 160 mL of water, and NaN3 (70.2 g, 1077.9 mmol) and NH4Cl (67.2 g, 1257.9 mmol) were added to the solution. oThe mixture was stirred at °C overnight. Brine was added to the reaction mixture and the mixture was extracted with EA (3 x 1 L). The organic layers were combined and concentrated under vacuum. The residue was purified by silica gel column flash chromatography (eluent: PE:EA = 10:1) to give a white solid KHC-14 (130.0 g, 95.59%).

[0189] Compound KHC-15: KHC-14 (125.6 g, 332.4 mmol) was dissolved in 1000 mL of CH3CN, and NaI (249.3 g, 1662.0 mmol) was added to the solution. The solution was stirred at room temperature for 30 min, and then TMSCl (144.9, 1329.6 mmol) was added dropwise to the reaction solution. The reaction was stirred at room temperature for 4 h. Brine was added to the reaction mixture, and the mixture was extracted with EA (3 x 1 L). The organic layers were combined and concentrated under vacuum. The residue was purified by silica gel column flash chromatography (eluent: PE:EA = 10:1) to give white solid KHC-15 (72.0 g, 75.20%).

[0190] Compound KHC-16: KHC-15 (72.0 g, 250.0 mmol) was dissolved in 1000 mL of CH3OH, and I2 (19.0 g, 75.0 mmol) was added to the solution. The reaction solution was heated to 60°C and kept stirring for 12 hours, then concentrated under vacuum. The residue was purified by silica gel column flash chromatography (eluent: PE:EA = 10:1) to obtain a white solid KHC-16 (53.0 g, 63.50%).

[0191] Compound KHC-17: Trimethylsilylacetylene (77.8 g, 793.0 mmol) was taken in 1000 mL of THF and n-butyllithium solution (1.6 m, 329.0 mmol, 205.6 ml) was added at -78°C. The reaction solution was kept stirring for 2 hours. Compound KHC-16 (53.0 g, 158.6 mmol) in 400 mL of THF was then added to the reaction solution. The mixture was stirred at -78°C for 2 hours and gradually heated to 0°C before being poured into saturated NH4Cl solution. The mixture was extracted with EA (800 mL x 3). The organic layers were combined and concentrated under vacuum. The residue was purified by chromatography column (eluent: PE:EA = 10:1) to obtain white solid KHC-17 (56.0 g, 81.55%).

[0192] Compound KHC-18: KHC-17 (56.0 g, 129.3 mmol) in 800 mL of THF was mixed with 1.0 M TBAF (129.3 mmol, 129.3 ml) at 0° C., and the mixture was kept stirring for 1 h. Brine was added to the reaction mixture, and the mixture was extracted with EA (3×1 L). The organic layers were combined and concentrated under vacuum. The residue was purified by silica gel column flash chromatography (eluent: PE:EA=5:1) to give a white solid KHC-18 (43.0 g, 92.30%).

[0193] Compound KHC-19: KHC-18 (38.0 g, 105.6 mmol) in 800 mL of THF was mixed with 1.0 M HCl to pH=3, and the mixture was kept stirring at room temperature for 12 h. Brine (1.0 L) was added to the reaction mixture, and the mixture was extracted with EA (3×1 L). The organic layers were combined and concentrated under vacuum. The residue was purified by silica gel column flash chromatography (eluent: PE:EA=5:1) to give a white solid KHC-19 (32.0 g, 96.50%).

[0194] Compound KHC-20: Methanesulfonic acid (148.0 g, 1541.6 mmol) was also mixed with 1000 mL of CH2Cl2, and KHC-19 (32.0 g, 101.9 mmol) in CH2Cl2 (1000 mL) was added dropwise to the solution. The reaction solution was stirred for 60 o C for 2 h and cooled to room temperature. Brine (1.0 L) was added to the reaction mixture and the mixture was extracted with CH2Cl2 (3 x 1.0 L). The organic layers were combined and concentrated under vacuum. The residue was purified by silica gel column flash chromatography (eluent: PE:EA = 10:1) to give a white solid KHC-20 (20.0 g, 62.50%).

[0195] Compound KHC-21: Compound KHC-20 (20.0 g, 63.7 mmol) was dissolved in 500 mL of THF, and 10% Pd / C (3.0 g) was added to the solution. The solution was then hydrogenated under H2 gas. The reaction solution was stirred at room temperature for 2 days, and then filtered. The filtrate was concentrated under vacuum to obtain a crude product. The crude product was then purified by silica gel column flash chromatography (eluent: PE:EA=15:1) to obtain a white solid KHC-21 (17.0 g, 84.40%).

[0196] Compound KH045: In a 2000 mL three-neck flask, FeCl3 (23.0 g, 142.0 mmol) and LiCl (13.5 g, 321.4 mmol) were mixed under N2, and 800 mL of anhydrous THF was added. The mixture was kept stirring at room temperature for 20 minutes and then cooled to -40 °C. CH3MgBr (3 M, 190 mL, 570.0 mmol) was added dropwise to the solution, followed by -40 °C. o Stirring was continued for 30 min at -20 °C. KHC-21 (17.0 g, 53.8 mmol) in anhydrous THF (200 mL) was added dropwise to the above reaction solution, and then the solution was cooled to -20 °C. oThe mixture was heated to °C and kept stirring for 4 h. When TLC monitoring of the reaction showed the reaction was complete, the reaction solution was quenched with saturated NH4Cl (40 mL) and the mixture was extracted with EA (3 x 1.0 L). The combined organic layer was washed with saturated brine I and dried over anhydrous Na2SO4. Concentration under vacuum gave the crude product. The crude product was then purified by flash chromatography on silica gel (eluent: PE / EA = 15:1) to give a white solid KH045 (10.2 g, yield 57.10%). 1 H NMR (400 MHz, CDCl3) δ 2.34 - 2.25 (m, 1H), 2.14 (s, 3H), 2.00 (t, J = 11.4 Hz, 1H), 1.87 - 1.78 (m, 1H), 1.75 - 1.54 (m, 9H), 1.51 - 1. 43 (m, 2H), 1.39 - 1.30 (m, 4H), 1.27 - 1.13 (m, 7H), 1.09 - 0.84 (m, 8H).

[0197] [ka]

[0198] Example 41: Synthesis of compound KH046

[0199] [ka]

[0200] Compound KHC-22 and Compound KHC-23: Compound KH045 (1.50 g, 4.50 mmol) was dissolved in 40 mL of CH3OH, and then Br2 (1.08 g, 6.75 mmol) was added dropwise to the solution. After reacting at room temperature for 4 h, the reaction solution changed color from orange to pale yellow. When TLC monitoring of the reaction showed the reaction was complete, water (30 mL) was added to the reaction mixture, and the mixture was extracted with EA (2 x 65 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by flash chromatography on silica gel (eluent: CH2Cl2) to obtain white solid KHC-22 (1.19 g, 64.34%) and white solid KHC-23 (0.33 g, 17.84%).

[0201] Compound KH046: KHC-22 (50 mg, 0.12 mmol) was dissolved in 5 mL of DMSO, followed by the addition of K2CO3 (21 mg, 0.15 mmol) and 8-fluoro-4-hydroxyquinazoline (25 mg, 0.15 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone = 4:1) to obtain a white solid KH046 (33 mg, 55.56%). 1 H NMR (400 MHz, CDCl3) δ 8.06 (d, 1H), 7.88 (s, 1H), 7.55 - 7.40 (m, 2H), 4.80 (q, 2H), 2. 44 (dd, 1H), 2.04 - 2.01 (m, 1H), 1.91 - 1.88 (m, 1H), 1.84 - 1.16 (m, 21H), 1.1 5 - 0.80 (m, 8H).

[0202] Example 42: Synthesis of compound KH047

[0203] [ka]

[0204] Compound KH047: KHC-22 (50 mg, 0.12 mmol) was dissolved in CH3CN (5 mL), followed by the addition of Cs2CO3 (49 mg, 0.15 mmol) and 5-mercapto-1-methyl-1H-tetrazolium (17 mg, 0.15 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone = 4:1) to obtain a white solid KH047 (51 mg, 50.12%). 1 H NMR (400 MHz, CDCl3) 4.40 (dd, 2H), 3.97 (s, 3H), 2.48 (dd, 1H), 2.05 - 1.99 (m, 1H), 1.93 - 1.82 (m, 1H), 1.83 - 1.14 (m, 21H), 1.13 - 0.70 (m, 8H).

[0205] Example 43: Synthesis of compound KH048

[0206] [ka]

[0207] Compound KH048: KHC-22 (60 mg, 0.14 mmol) was dissolved in 5 mL of DMSO, followed by the addition of K2CO3 (58 mg, 0.42 mmol) and 6-fluoropyridine[3,4-d]pyrimidin-4-one (69 mg, 0.42 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed that the reaction was complete, water (10 mL) was added to the reaction mixture, and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / CH3OH=40:1) to obtain a white solid KH048 (37 mg, 50.12%). 1 H NMR (400 MHz, CDCl3) δ 8.82 (s, 1H), 7.79 (s, 1H), 7.66 (d, 1H), 4.80 (dd, 2H), 2.44 (dd, 1H), 2.05 - 1.99 (m, 1H), 1.93 - 1.82 (m, 1H), 1.83 - 1.14 (m, 21H), 1.13 - 0.70 (m, 8H).

[0208] Example 44: Synthesis of compound KH049

[0209] [ka]

[0210] Compound KH049: KHC-22 (60 mg, 0.15 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of Cs2CO3 (62 mg, 0.19 mmol) and 2-mercaptobenzoxazole (29 mg, 0.19 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone = 4:1) to obtain a white solid KH049 (42 mg, 42.92%). 1 H NMR (400 MHz, CDCl3) δ 7.55 (d, 1H), 7.42 (d, 1H), 7.34 - 7.24 (m, 2H), 4.33 (dd, 2H), 2.57 (dd, 1H), 2.05 - 1.99 (m, 1H), 1.93 - 1.82 (m, 1H), 1.83 - 1.14 (m, 21H), 1.13 - 0.70 (m, 8H).

[0211] Example 45: Synthesis of compound KH050

[0212] [ka]

[0213] Compound KH050: KHC-22 (60 mg, 0.15 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of Cs2CO3 (62 mg, 0.19 mmol) and 3-mercapto-4-methyl-4H-1,2,4-triazole (22 mg, 0.19 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed that the reaction was complete, water (10 mL) was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH = 70:1) to obtain a white solid KH050 (17 mg, 25.41%). 1 H NMR (400 MHz, CDCl3) δ 8.22 (s, 1H), 4.37 (dd, 2H), 3.68 (s, 3H), 2.50 (dd, 1H), 2.10 - 1.97 (m, 1H), 2.06 - 2.02 (m, 1H), 1.79 - 1.14 (m, 21H), 1.12 - 0.79 (m, 8H).

[0214] Example 46: Synthesis of compound KH051

[0215] [ka]

[0216] Compound KH051: KHC-22 (60 mg, 0.15 mmol) was dissolved in 5 mL of DMSO, followed by the addition of K2CO3 (58 mg, 0.42 mmol) and 3-hydroxy-1H-1,2,4-triazole (36 mg, 0.42 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=40:1) to obtain a white solid KH051 (27 mg, 46.36%). 1 H NMR (400 MHz, CDCl3) δ 9.57 (s, 1H), 7.42 (s, 1H), 4.46 (q, 2H), 2.34 (dd, 1H), 2.07 - 1.96 (m, 1H), 1.88 - 1.82 (m, 1H), 1.79 (s, 21H), 1.11 - 0.81 (m, 8H).

[0217] Example 47: Synthesis of Compound KH052 and Compound KH053

[0218] [ka]

[0219] Compound KH052 and Compound KH053: KHC-22 (100 mg, 0.24 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of Cs2CO3 (234 mg, 0.72 mmol) and 1H-tetrazole (50 mg, 0.72 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed that the reaction was complete, water (10 mL) was added to the reaction mixture, and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried with anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=30:1) to obtain white solid KH6070069-1 (19 mg, 19.74%) and white solid KH6070069-2 (44 mg, 45.72%), respectively. 1 H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H), 5.49 (s, 2H), 2.33 (dd, 1H), 2.05 - 2.01 (m, 1H), 1.94 - 1.84 (m, 1H), 1.83 - 1.15 (m, 21H), 1.14 - 0.82 (m, 8H). 1 H NMR (400 MHz, CDCl3) δ 8.72 (s, 1H), 5.29 (dd, 2H), 2.41 (dd, 1H), 2.06 - 2. 01 (m, 1H), 1.95 - 1.85 (m, 1H), 1.85 - 1.15 (m, 21H), 1.14 - 0.82 (m, 8H).

[0220] Example 48: Synthesis of compound KH054

[0221] [ka]

[0222] Compound KH054: KHC-22 (60 mg, 0.15 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of Cs2CO3 (62 mg, 0.19 mmol) and 2-hydroxyoxazole[4,5-b]pyridine (26 mg, 0.19 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH=70:1) to obtain a white solid KH054 (17 mg, 42.92%). 1 H NMR (400 MHz, CDCl3) δ 7.25 (d, 1H), 7.01 (d, 1H), 6.69 (t, 1H), 5.11 (q, 2H), 2.40 (dd, 1H), 2.08 - 1.98 (m, 1H), 1.93 - 1.83 (m, 1H), 1.82 - 1.14 (m, 21H), 1.15 - 0.81 (m, 8H).

[0223] Example 49: Synthesis of compound KH055

[0224] [ka]

[0225] Compound KH055: KHC-22 (60 mg, 0.15 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of Cs2CO3 (156 mg, 0.48 mmol) and 4-cyanopyrazole (45 mg, 0.48 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH = 30:1) to obtain a white solid KH055 (51 mg, 50.12%). 1 H NMR (400 MHz, CDCl3) δ 7.83 (s, 1H), 7.81 (s, 1H), 4.99 (q, 2H), 2.32 (dd, 1H), 2.05 - 2.01 (m, 1H), 1.92 - 1.83 (m, 1H), 1.82 - 1.15 (m, 21H), 1.14 - 0.81 (m, 8H).

[0226] Example 50: Synthesis of compound KH056

[0227] [ka]

[0228] Compound KH056: KHC-23 (40 mg, 0.10 mmol) was dissolved in 5 mL of CH3CN, followed by the addition of Cs2CO3 (198 mg, 0.3 mmol) and 4-cyanopyrazole (28 mg, 0.30 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2 x 20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: CH2Cl2 / CH3OH = 30:1) to obtain a white solid KH056 (12 mg, 23.30%). 1 H NMR (400 MHz, CDCl3) δ 8.22 (s, 1H), 8.14 (s, 1H), 7.92 (s, 1H), 7.84 (s, 1H), 7.02 (s, 1H), 2.10 (dd, 1H), 2.05 - 2.00 (m, 1H), 1.87 - 1.78 (m, 1H), 1.78 - 1.14 (m, 21H), 1.12 - 0.79 (m, 8H).

[0229] Example 51: Synthesis of compound KH057

[0230] [ka]

[0231] Compound KH057: KHC-22 (60 mg, 0.15 mmol) was dissolved in 5 mL of DMSO, followed by the addition of Cs2CO3 (143 mg, 0.44 mmol) and 2-hydroxybenzoxazole (59 mg, 0.44 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed that the reaction was complete, water (10 mL) was added to the reaction mixture, and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone=3:1) to obtain a white solid KH057 (30 mg, 42.92%). 1 H NMR (400 MHz, CDCl3) δ 7.24 - 7.19 (m, 1H), 7.17 - 7.07 (m, 2H), 6.75 - 6.65 (m, 1H), 4.58 (s, 2H), 2.40 (dd, 1H), 2.08 - 1.98 (m, 1H), 1.93 - 1.83 (m, 1H), 1.82 - 1.14 (m, 21H), 1.15 - 0.81 (m, 8H).

[0232] Example 52: Synthesis of compound KH058

[0233] [ka]

[0234] Compound KH058: KHC-22 (80 mg, 0.19 mmol) was dissolved in 5 mL of DMSO, followed by the addition of Cs2CO3 (190 mg, 0.58 mmol) and 8-methyl-4-quinazolinone (93 mg, 0.58 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone=3:1) to obtain a white solid KH058 (28 mg, 30.01%). 1 H NMR (400 MHz, CDCl3) δ 8.13 (d, 1H), 7.88 (s, 1H), 7.61 (d, 1H), 7.39 (t, 1H), 4.80 (dd, 2H), 3.49 (s, 3H), 2.45 (dd, 1H), 2.03 - 2.01 (m, 1H), 1.92 - 1.84 (m, 1H), 1.83 - 1.16 (m, 21H), 1.14 - 0.80 (m, 8H).

[0235] Example 53: Synthesis of compound KH059

[0236] [ka]

[0237] Compound KH059: KHC-22 (80 mg, 0.19 mmol) was dissolved in 5 mL of DMSO, followed by the addition of Cs2CO3 (190 mg, 0.58 mmol) and 8-hydroxy-1,7-naphthyridine (85 mg, 0.58 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed that the reaction was complete, water (10 mL) was added to the reaction mixture, and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone=3:1) to obtain a white solid KH058 (28 mg, 30.89%). 1 H NMR (400 MHz, CDCl3) δ 8.86 (d, 1H), 7.88 (d, 1H), 7.54 (dd, 1H), 6.96 (d, 1H), 6.45 (d, 1H), 4.86 (s, 2H), 2.45 (dd, 1H), 2.09 - 1.95 (m, 1H), 1.87 - 1.83 (m, 1H), 1.80 - 1.15 (m, 21H), 1.12 - 0.76 (m, 8H).

[0238] Example 54: Synthesis of compound KH060

[0239] [ka]

[0240] Compound KH060: KHC-22 (100 mg, 0.24 mmol) was dissolved in 5 mL of DMSO, followed by the addition of Cs2CO3 (156 mg, 0.48 mmol) and 3-hydroxy-4-methyl-5-methoxy-4H-1,2,4-triazole (62 mg, 0.48 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed that the reaction was complete, water (10 mL) was added to the reaction mixture and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone=4:1) to obtain a white solid KH058 (56 mg, 50.72%). 1 H NMR (400 MHz, CDCl3) δ 4.54 - 4.40 (m, 2H), 3.93 (s, 3H), 3.12 (s, 3H), 2.29 (dd, 1H), 2.03 - 1.99 (m, 1H), 1.85 - 1.82 (m, 1H), 1.77 - 1.13 (m, 21H), 1.10 - 0.81 (m, 8H).

[0241] Example 55: Synthesis of compound KH061

[0242] [ka]

[0243] Compound KH061: KHC-22 (80 mg, 0.19 mmol) was dissolved in 5 mL of DMSO, followed by the addition of Cs2CO3 (156 mg, 0.48 mmol) and 2-hydroxyquinoline (84 mg, 0.58 mmol). The reaction was carried out at room temperature overnight. When TLC monitoring of the reaction showed that the reaction was complete, water (10 mL) was added to the reaction mixture, and the mixture was extracted with EA (2×20 mL). The combined organic layer was washed with saturated NaCl and dried over anhydrous Na2SO4. The solvent was distilled under reduced pressure to obtain the crude product. The crude product was purified by TLC (eluent: PE / acetone=4:1) to obtain a white solid KH058 (45 mg, 49.76%). 1 H NMR (400 MHz, CDCl3) δ 8.05 (d, 1H), 7.75 (dd, 2H), 7.61 (t, 1H), 7.39 (t, 1H), 7.05 (d, 1H), 5.15 (s, 2H), 2.43 (dd, 1H), 2.04 - 2.00 (m, 1H), 1.86 - 1.83 (m, 1H), 1.78 - 1.12 (m, 21H), 1.10 - 0.80 (m, 8H).

[0244] Example 56: In vitro cell viability assay The control compounds used in the present invention have the chemical structures illustrated below:

[0245] [ka]

[0246] Detailed synthesis of the control compound was prepared with reference to CN105339381B.

[0247] The present invention relates to recombinant GABA A Two subunits of the receptor, namely α1β2γ2 and α4β3δ, are applied to evaluate the performance of exemplary compounds in vitro by patch clamp electrophysiology.

[0248] 56.1 Electrophysiological Test Solutions (Extracellular and intracellular fluid composition) Extracellular solution: 140mM NaCl, 5mM CsCl, 2mM CaCl2·2H2O, 1mM MgCl2·6H2O, 5mM HEPES, 10mM D-glucose, pH=7.4 (NaOH).

[0249] Intracellular solution: 130mM CsCl, 0.1mM CaCl2·H2O, 2mM MgCl2·6H2O, 1.1mM EGTA, 5mM Na2-ATP, 10mM HEPES, pH=7.2 (CsOH).

[0250] The prepared intracellular solution was dispensed at 1 mL per tube, frozen, and stored in a refrigerator at -20°C. Freshly thawed intracellular solution was used for the experiment every day. All intracellular solutions were consumed within 3 months.

[0251] [56.2 Cell lines with stable expression of ion channels]

[0252] [Table 1]

[0253] [56.3 Cell culture] [56.3.1 GABA A (α1β2γ2) cell culture] GABA A A HEK293 cell line stably expressing the (α1β2γ2) receptor was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 800 μg / mL G418, 200 μg / mL hygromycin B, and 100 μg / mL zeocin. Cells were grown in a humidified incubator at 37°C with 5% carbon dioxide.

[0254] Cell passaging: Old medium was removed and cells were washed once with PBS. Then, 1 mL of 0.25%-trypsin-EDTA solution was added and incubated at 37°C for 0.5 min. After the cells were detached from the bottom of the dish, 5 mL of complete medium pre-warmed at 37°C was added. Cell aggregates were dissociated by gentle pipetting. After transferring the cell suspension to a sterile centrifuge tube, the cell suspension was spun at 1000 rpm for 5 min to collect the cells. 2.5×10 5 The cells were expanded or maintained by seeding the cells.

[0255] To maintain electrophysiological performance, cell density should not exceed 80%.

[0256] Before manual patch clamp testing, cells were detached using 0.25% trypsin-EDTA solution. 3 Cells were plated on cover slips, cultured in 24-well plates (final medium volume: 500 μL) and tested by patch clamp after 18 hours.

[0257] [56.3.2 GABA A (α4β3δ) cell culture] The HEK293 cell line was cultured in DMEM containing 10% fetal bovine serum at 37° C. under 5% carbon dioxide.

[0258] Cell passage: Old medium was removed and cells were washed once with PBS. Then, 1 mL of 0.25%-trypsin-EDTA solution was added to digest the cells. The culture dish was incubated at 37°C for 0.5 min in a pre-heated incubator. As soon as the cells were detached, about 5 mL of complete medium pre-heated at 37°C was added. Cell aggregates were dissociated by gentle pipetting. After transferring the cell suspension to a sterile centrifuge tube, the cell suspension was spun at about 1000 rpm for 5 min. 2.5 × 10 cells were placed in a 6 cm dish (final medium volume: 5 mL). 5 Cells were expanded or maintained by seeding cells. For transfection, 8 × 103 Cells were plated onto cover slips and cultured in 24-well plates (final medium volume: 5 mL).

[0259] Transfection: On day 2, GABA A4 Transfection of 12 wells (α4, β3, δ plasmid ratio 1:1:1) was performed. X-tremeGENE HP DAN transfection reagent kit was used. The ratio of plasmid to transfection reagent was 1μg:2μL. The amount of plasmid in the 24-well plate was 0.5μg per well and transfection reagent was 1μL. To prepare 12 wells, the following specific steps were taken: 600μL of Opti-MEM was added to a sterile centrifuge tube with 6μg of plasmid and mixed thoroughly. Then, 12μL of transfection reagent was added. After incubation at room temperature for 15 minutes, it was mixed thoroughly. Then, the transfection complex was inoculated (50μL per well) onto the cells and the transfection complex was mixed by gentle vortexing.

[0260] The mixture was replaced on the third day, and patch clamping was performed on the fourth day.

[0261] [56.4 Patch clamp testing] Glass pipettes (BF 150-86-10, Sutter Instruments) were pulled using a micropipette puller (P97, Sutter Instruments). Glass pipettes were manipulated using a micromanipulator (MP285, Sutter Instruments) under a microscope (IX71, Olympus). After contacting the cell, a high seal resistance (GΩ) was achieved by applying slight suction. After reaching a high seal, fast capacitance (pF) compensation was performed to rupture the membrane. After achieving whole-cell mode, cell capacitance (pF) compensation was performed from whole-cell capacitance compensation. No leakage subtraction was performed.

[0262] Test and control solutions were flowed via a gravity-fed solution delivery system into a recording chamber attached to the stage of an inverted microscope. Solutions were collected from the recording chamber by vacuum suction during the experiment. Each concentration was tested in duplicate. All tests were performed at room temperature.

[0263] GABA A1 The whole-cell model current experimental protocol for recording receptors was as follows: at tight seal, cells were at a holding potential of -70 mV and peak currents were recorded in gap-free mode. Cells were challenged with 3 μM GABA for active currents. After applying the test substances for 30 seconds, 3 μM GABA was applied for each concentration of test substance, followed by a 2-minute wash with extracellular solution. Finally, 100 μM GABA was used as a positive control. Data were collected by an EPC-10 amplifier and stored in PatchMaster (HEKA) software.

[0264] GABA A4 The experimental protocol for whole-cell model current recording of receptors was as follows: at tight seal, cells were held at -70 mV and peak currents were recorded in gap-free mode. Cells were challenged with 10 nM GABA for activation currents. After applying the test substances for 30 seconds, each concentration of test substance was applied with 10 nM GABA, followed by a 2-minute wash with extracellular solution. Finally, 10 μM GABA was used as a positive control. Data were collected by an EPC-10 amplifier and stored in PatchMaster (HEKA) software.

[0265] [56.5 Data Quality Standards] The following criteria are used to determine whether the data are acceptable: (1) Electrode resistance<5MΩ (2) Seal resistance > 1GΩ (3) Starting access resistance <15MΩ (4) Access resistance end <15MΩ (5) There is no obvious natural current decay.

[0266] (6) When the membrane potential is -70mV, there is no obvious leakage current.

[0267] 56.6 Data Analysis GABA A1 For detection of 3 μM GABA currents and various concentrations of test compounds, each was normalized to 100 μM GABA currents.

[0268]

number

[0269] The activation rate corresponding to each concentration was then calculated. A4 For detection of 10 nM GABA currents and various concentrations of test compounds, each was normalized to 10 μM GABA currents.

[0270]

number

[0271] The percent activation corresponding to each concentration was then calculated. The mean, standard deviation and standard error were calculated for each test group. Nonlinear regression was used to calculate the EC50 value: Y=Bottom+(Top-Bottom) / (1+10^((LogEC50-X)×HillSlope)) To fit the data to a concentration response, EC50 was the concentration giving a half-maximal effect and Hillslope was the Hill coefficient. Curve fitting and EC50 calculations were performed using Graphpad 5.0 software.

[0272] [56.7 In vitro experiment results]

[0273] [Table 2]

[0274] A:>80%, B:60%~80%(including 60%), C:40%~60%(including 40%), D:20%~40%(including 20%), E:0~20%.

[0275] Table 1 shows the potency of exemplary compounds at concentrations of 0.1 μM and 1 μM. The potency is the ratio of the GABA concentration to the peak current produced only by 100 μmol of GABA. A1 Based on the ratio of peak currents produced at the receptors, the ratio was multiplied by 100%. A1 The peak currents produced at the receptors were 100% higher for the exemplary compounds than for the GABA receptors at these two concentrations, as well as 3 μmol of GABA. A1 The mechanism was to act on the receptor.

[0276] [Table 3]

[0277] E max is the ratio of GABA to the peak current induced only by 100 μmol GABA A1 It is defined as the ratio of the peak current produced at the receptor to the total current produced by the receptor, multiplied by 100%. A1 The peak current generated at the receptor was measured by comparing the results of the exemplary compound with 3 μmol of GABA. A1 It acts on the receptors.

[0278] [Table 4]

[0279] N / A indicates that the current does not change with concentration.

[0280] E max is the ratio of the peak current induced by GABA alone to the peak current induced by GABA alone. A1 It is defined as the ratio of the peak current produced at the receptor to the total current produced by the receptor, multiplied by 100%. A1 The peak current generated at the receptor is the peak current generated at the receptor when the exemplary compound is A1It acts on the receptor alone or together with 10 nmol of GABA.

[0281] Example 57: Brain and plasma pharmacokinetics after administration [1. Protocol] [1.1 Test drug] KH022 of the present invention and the control described in Example 56 [1.2 Animals] The experimental animals were CD-1 mice.

[0282] [1.3 Administration] Preparation of test compounds for intragastric administration using 30% SBECD in water. On the first day of the experiment, animals in group 1 were intraperitoneally injected with a solution of KH022 or control at a dose of 5 mL / kg. Before administration, animals were weighed and the administration volume was calculated according to body weight. Whole blood samples (approximately 0.03 ml per group) were collected at specific times by saphenous vein puncture (or other suitable collection site). Blood samples were immediately processed to plasma by centrifugation at approximately 4°C and 3,200 g for 10 min, quickly placed in dry ice, and kept below -20°C until LC / MS / MS analysis. At each time point, animals were euthanized using CO2, after which brain tissue was collected, rinsed, and dried using saline. It was homogenized using 4 times the brain weight (g) volume of 15 mM PBS (pH 7.4):MeOH = 2:1. After homogenization, samples were transferred to labeled centrifuge tubes, quickly placed on dry ice, and stored below -20°C for LC-MS / MS analysis.

[0283] 2. Data Analysis The concentrations of test compounds in the dose formulation samples were determined by LC / UV, and the calibration curve included at least six calibration standards and was 2≥ 0.999. The concentrations of test compounds in biological matrices were measured using an LC / MS / MS method. Retention times of test compounds or internal standards, chromatogram acquisition and chromatogram integration were processed by Software Analyst (Applied Biosystems), and data statistics were processed by Software Watson LIMS (Thermo Fisher Scientific) or Analyst (Applied Biosystems). The units of analyte concentrations in samples were in ng / mL, with three significant digits reserved and all values ​​expressed as percentages (such as deviation % and coefficient of variation %) rounded to one decimal place. WinNonlin TM Plasma concentrations were treated using a noncompartmental model in Version 6.3 (Pharsight, Mountain View, Calif.) pharmacokinetic software, and pharmacokinetic parameters were calculated using the linear-log trapezoidal method.

[0284] [Experimental Results] As shown in Figures 1 and 2, at the same dose, KH022 is eliminated more slowly in mouse brain than the control (no detection of control in brain at 8 hours), and the content of KH022 in mouse brain is 2.5 times that of the control at 2 hours.

[0285] [57.3 Anti-anxiety tests in mice] [57.3.1 Light / Dark Swap Box] The light-dark alternating box is a standard and well-characterized assay for the anxiolytic effect of exemplary compounds. Mice naturally avoid the light box because light makes them evasive and stressful. However, their exploration behavior also encourages them to explore the light box. The increase in the time to the light box by exemplary compounds reflects the anxiolytic effect on mice. Experimental mice were randomly divided into 5 groups based on body weight, including a negative control group, two different dose groups (1 mg / kg and 3 mg / kg) of test compounds (KH004 or KH022). Every group had 10 male mice. The mice were administered the corresponding dose for 5 consecutive days in advance for test intervention, and the anxiolytic experiment was performed 30 minutes after the last administration. The retention time in the light box was selected as the main index for evaluating the anxiolytic effect of KH004 and KH022.

[0286] [Experimental Results]

[0287] [Table 5]

[0288] Note: All data in the table are expressed as mean ± standard deviation (mean ± SD). Statistical analysis was performed on 10 animals in each experimental group. * P < 0.05, ** P < 0.01, *** P<0.001, **** P<0.0001 represents a difference between experimental and negative control animals.

[0289] [57.3.2 Elevated Plus Maze (EPM) Test] The EPM for exploratory behavior was used to evaluate general motor and anxiety-like behavior, consisting of two open arms and two closed arms extending from a common central platform, which form an anxiety-like symptom. Anxiolytic compounds reduce the anxiety-conflict state of animals in the test system. Experimental mice were randomly divided into four groups based on body weight, including a negative control group, two different dose groups (1 mg / kg and 3 mg / kg) of test compounds (KH004 or KH022). Every group had 10 male mice. For the test intervention, the mice were administered the corresponding dose for five consecutive days in advance, and the anxiolytic experiment was performed 30 minutes after the last administration. The percentage of the mouse's open arm retention time (latency time) was used as the main index to evaluate the anxiolytic effect of KH004 and KH022, and the results are shown in Table 5.

[0290] [Table 6]

[0291] Note: All data in the table are expressed as mean ± standard deviation (mean ± SD). Statistical analysis was performed on 10 animals in each experimental group. * P < 0.05, ** P < 0.01, *** P<0.001, **** P<0.0001 represents the difference between each experimental group and the negative control group of animals.Conclusion: KH004 and KH022 significantly increased the percentage of time that animals spent in the open arms, indicating anxiolytic effects.

[0292] [57.3.3 Experiments on side effects during administration] Drugs acting on GABA(A) receptors can cause behavioral paralysis (side effects), so mice were observed for side effects during administration in the elevated plus maze experiment. Three behavioral manifestations were observed for 10 mice per group: walking, agility, and prone behavior. "+" indicates severity. Three "+" is the most severe, and the time required to resume normal behavior exceeds 60 minutes. The positive drug is the control compound described in Example 56, and the results are shown in Table 6.

[0293] KH004 and KH022 have fewer side effects compared to the positive drugs in Table 6.

[0294] [Table 7]

Claims

1. A pharmaceutical composition comprising a compound of formula (II), or a pharma- ceutically acceptable salt thereof, 【Chemistry 1】 During the ceremony, R1 is hydrogen or halogen substituted or unsubstituted C1-3 alkyl; R2 is hydrogen, halogen, halogen unsubstituted or substituted C1-6 alkyl, or halogen unsubstituted or substituted C1-6 alkoxy; X is CH ２ and R5 is selected from the group consisting of: 【Chemistry 2】 During the ceremony, R6 is H, halogen, CN, CF3, NO2, halogen unsubstituted or substituted C1-6 alkyl, or halogen unsubstituted or substituted C1-6 alkoxy; Pharmaceutical compositions.

2. 1. A pharmaceutical composition comprising a compound, or a pharma- ceutically acceptable salt thereof, The compound is selected from the group consisting of: 【Chemistry 3】 【Chemistry 4】 Pharmaceutical compositions.

3. 3. The pharmaceutical composition according to claim 1 or 2, comprising a pharma- ceutically acceptable excipient.

4. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is administered orally, subcutaneously, intravenously, or intramuscularly.

5. Use of the pharmaceutical composition according to any one of claims 1 to 4 in the preparation of a medicament for preventing or treating a neurological disease.

6. 6. The use according to claim 5, wherein the neurological disorder is selected from the group consisting of sleep disorders, mood disorders, schizophrenia spectrum disorders, spastic disorders, memory and / or cognitive disorders, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and amputation syndromes, or tinnitus.

7. The mood disorder is depression, 7. The use according to claim 6, wherein the depression is major mood disorder, severe depressive disorder, persistent depressive disorder, premenstrual syndrome, substance or drug induced disorder, other physical illness disorder, or other specified depressive disorder and unspecified depressive disorder.

8. 6. The use according to claim 5, wherein the neurological disorder is mild depression, moderate depression, severe depression, or postpartum depression.

Images